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Irritable Bowel Syndrome (IBS) is a complex disorder of unknown etiology. Research into 
the pathophysiology of IBS suggests the involvement of psychological, hormonal, 
immunological, genetic, cardiovascular, and autonomic nervous system factors, as well as 
peripheral and central sensitization of pain signals in the etiology and/or maintenance of IBS. 
Visceral hyperalgesia is consistently observed in IBS patients. However, recent investigations 
have found evidence of somatic hyperalgesia, not seen in earlier studies, suggesting the 
possibility of a dysfunction in central pain regulatory mechanisms.  
 Evidence suggests a role for central sensitization in IBS pain. Psychophysical 
investigations into dysregulation of the endogenous pain regulatory mechanisms of temporal 
summation and diffuse noxious inhibitory controls (DNIC) have been consistently 
demonstrated in other chronic pain conditions such as Fibromyalgia and Temporomandibular 
Disorder, which show high comorbidity with IBS.  
 The primary objective of this investigation was to explore the role of central 
sensitization in IBS pain by assessing both efferent (DNIC) and afferent (temporal 
summation) central modulation of nociception in IBS patients. Group differences in 
psychological, autonomic nervous system, and general pain measures were also assessed. 
 Forty eight pre-menopausal females (27 with IBS) participated in this investigation. 
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No group differences were seen in temporal summation or the DNIC effect on temporal 
summation. Similarly, no group differences were seen in any general pain measures or in 
sympathetic tone. IBS subjects reported significantly greater stress than Controls on 
measures of; state anxiety, depression, catastrophizing, and anger-out expression. IBS 
subjects also demonstrated significantly lower levels of DNIC than Controls during noxious 
tonic conditioning stimuli. However, non-noxious conditioning stimuli also produced an 
apparent DNIC effect in a counterbalanced design. After controlling for non-specific effects 
occurring in the non-painful conditioning protocol (distraction, and psychological measures 
associated with DNIC), IBS subjects continue to show deficient DNIC (p < 0.01).  
 This is the second investigation that has attempted to account for non-specific effects 
in the investigation of DNIC. Only by controlling for non-specific effects, can evidence of 
deficient DNIC can be attributed to dysregulation in endogenous analgesic mechanisms.   
Further studies are needed to elucidate whether deficient DNIC is a cause or consequence of 
IBS pain.  
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Irritable Bowel Syndrome (IBS) is characterized by chronic abdominal pain that is associated 
with changes in bowel function and is one of the most common reasons for visits to primary 
care physicians or gastroenterologists (2.4 to 3.5 million visits/year) in the United States. 
Approximately 15 % of the U.S. population suffers from IBS (Drossman et al., 1993) and is 
more prevalent in women, with estimates ranging from a 2:1 ratio in community samples 
(Saito et al., 2000) to a 4:1 ratio in treatment seeking populations (Camilleri, 1999). In 1998, 
IBS accounted for direct health care costs totaling $1.6 billion (American Gastroenterological 
Association, 2001), and has been linked to a doubling of health care visits per year, from 4.5 
to 9.0 (Levy et al., 2000b). This may be due to the fact that only 50% of IBS patients are 
satisfied with the treatments for IBS that are currently available to them (Whitehead W.E. et 
al., 2004; Thompson et al., 1997).  
IBS patients, by definition, do not demonstrate any observed pathological condition. 
Although recent evidence suggests a role for serotonin reuptake transporter polymorphisms 
(Kim et al., 2004; Pata et al., 2002; Yeo et al., 2004), or dysregulated immunological activity 
(Gwee et al., 1999; Gwee et al., 2003; O'Mahony et al., 2005; Spiller, 2003) in some IBS 





Psychological Influences on Irritable Bowel Syndrome 
Psychological stress is known to precipitate symptoms in patients with IBS (Whitehead et al., 
1992). Although psychosocial factors affect motility in IBS and healthy controls, stress 
increases motility more so for patients with functional gastrointestinal disorders than for 
healthy controls (Drossman et al., 1997). In addition, levels of chronic life stress predict 
clinical outcome of IBS (Bennett et al., 1998) and psychological symptoms define severity 
and status in IBS (Drossman, 1999).  
 The evidence regarding the influence of psychological factors on IBS is mixed. It is 
known that IBS patients have an increased prevalence of psychiatric disorders, such as 
anxiety, depression, personality disorders, and somatization, compared to the general 
population. Gwee and colleagues (1996; 1999) showed that patients with acute gastroenteritis 
were more likely to develop IBS if they had higher levels of anxiety, somatization, and 
depression than those who did not develop IBS. However, Chun et al. (1999) reported that 
rectal hyperalgesia was not related to psychological distress, healthcare seeking behaviors, or 
general chronic functional pain disorders.  
In a review of the evidence for psychological influences on perception of abdominal 
pain, Whitehead and Paulson (1998) reported that 66% of IBS patients report pain at 
abnormally low rectal distensions. This finding did not correlate with anxiety or depression 
in IBS patients. IBS patients even rated sham distensions as painful, but control subjects did 
not. When psychological factors were controlled for, there was no difference between IBS 
and controls in pain ratings of sham distensions. This may indicate psychological factors 
played a role in IBS subjects identifying sham distensions as painful. In addition, 
manipulating attention and arousal with stress or relaxation, had a substantial effect on pain 
reports by IBS subjects. 
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Studies have shown that how a person responds to stress also influences pain 
sensitivity. Burns and colleagues (2004) demonstrated that an anger-out expression style was 
associated with higher pain intensity in patients not taking opioids, even after controlling for 
anxiety and depression. Similarly, Bruehl and colleagues (2003) found that greater anger-out 
scores on an anger management style questionnaire were associated with hypersensitivity to 
pain and  with a reduced naloxone blockade effect, indicative of impaired opioid anti-
nociception.  
 In a recent study, Granot and colleagues (2002) reported that scores on the 
Pain Catastrophizing Scale predicted postoperative pain following elective 
abdominal surgery. Gracely and colleagues (2004) suggested that catastrophizing 
influences pain perception, by increasing attention and anticipation, and emotional 
responses to pain. This was based on the fMRI findings that greater catastrophizing 
scores were associated with elevated activity in brain areas involved in anticipation 
of pain (medial frontal cortex and cerebellum), attention to pain (dorsal anterior 
cingulate cortex and dorsolateral prefrontal cortex), emotional aspects of pain 
(claustrum) and motor control, in FMS patients, after controlling for effects of 
depression. 
 Edwards and colleagues (2004) reported that elevated catastrophizing scores were 
unrelated to experimental pain thresholds during clinical pain conditions. However, after the 
pain was successfully treated, baseline catastrophizing scores were inversely related to pain 
threshold and pain tolerance measures. This suggests that catastrophizing may be a 
consequence of suffering from chronic pain. France and colleagues (2002a) showed that 
catastrophizing scores on the Coping Strategies Questionnaire were not related to the 
nociceptive flexion reflex, RIII, but was correlated with pain ratings in young healthy 
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subjects, suggesting that the relationship between catastrophizing and increased pain reports 
is not related to differential modulation of spinal nociception.  
 Psychiatric disorders and psychological distress are commonly associated with IBS, 
although a causal relationship has not been established. Houghton and colleagues (2002) 
found that hypnotherapy was successful in normalizing abnormal visceral sensitivity and 
reduced pain in IBS patients. This may suggest a role for the central nervous system in 
regulating visceral pain. 
 It has been suggested that IBS is actually several different disorders resulting from 
different etiologies (Rodrigues et al., 2005) Inflammation and immune dysfunction has 
recently been linked to IBS and genetic polymorphisms have also recently been identified in 
IBS patients (Pata et al., 2002; Kim et al., 2004; Yeo et al., 2004). Others have suggested that 
IBS is part of a broader disorder of pain dysregulation that includes other chronic pain 
disorders such as fibromyalgia (FMS) and temporomandibular disorders (TMD) (Siddall & 
Cousins, 2004; Aaron et al., 2000; Kleinbohl et al., 1999). Up to 80 % of IBS patients also 
have other gastrointestinal chronic pain disorders, such as dyspepsia or upper gastrointestinal 
pain. In addition, many patients with IBS also have somatic chronic pain conditions, such as 
FMS, and TMD and Veale and colleagues (1991) has shown that approximately 70% of FMS 
patients have chronic visceral pain.  
 The majority of IBS patients have been found to be hypersensitivity to balloon 
distension of the rectum, demonstrating higher pain ratings (Naliboff et al., 1997), lower 
visceral pain thresholds (Mertz et al., 1995) , and pain tolerance  (Whitehead et al., 1990) 
than controls. Although not all IBS patients demonstrate this hypersensitivity, visceral 
hyperalgesia is considered to be a biological marker for IBS (Chun et al., 1999; Mertz et al., 
1995). Whitehead and colleagues  (1998) reported that approximately two-thirds of IBS 
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patients have visceral hypersensitivity to rectal distensions. It is not known whether visceral 
hyperalgesia is a result of peripheral or central sensitization. Those investigators that suggest 
that IBS pain results from central dysregulation of pain processing differ in whether the 
dysfunction is in the brain or in the spinal cord. Recent brain imaging studies show 
differences in pain centers in the brain during noxious rectal distensions (Verne et al., 2003a; 
Mertz et al., 2000; Wilder-Smith et al., 2004), while other studies have demonstrated spinal 
cord involvement in IBS pain based on alterations in the nociceptive flexion (RIII) reflex 
during rectal distensions (France et al., 2002b). 
Contrary to earlier reports, most recent investigations have also demonstrated somatic 
hyperalgesia in IBS patients (Bouin et al., 2001; Verne et al., 2001; Verne et al., 2003b; 
Rodrigues et al., 2005). This new data suggests the possibility that IBS patients may suffer 
from a global dysregulation in central pain processing similar to that seen in other chronic 
pain disorders, such as Fibromyalgia (FMS) and temporomandibular disorders (TMD). 
Investigations to explore central sensitization in these and other chronic disorders have 
focused on two aspects of central sensitization, namely; 1) exaggerations in the wind-up 
phenomenon that facilitates ascending pain signals, and 2) deficits in DNIC (disinhibition), 
that normally provides tonic descending antinociceptive signals. Research consistently shows 
enhanced temporal summation of afferent pain signals as well as deficits in Diffuse Noxious 
Inhibitory Controls (DNIC) in FMS (Lautenbacher & Rollman, 1997; Staud et al., 2001; 
Staud et al., 2003) and TMD patients (Maixner et al., 1995; Maixner et al., 1998; Kashima et 
al., 1999; Sarlani et al., 2004) and TMD patients compared to healthy controls, leading these 
experts to conclude that this central alteration in pain signaling may be important in the onset 
or worsening of chronic pain symptoms (Edwards et al., 2003b; Staud & Rodriguez, 2006; 
Verne & Price, 2002).  
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Neurophysiology of Pain 
Pain occurs when noxious thermal, mechanical, or chemical, stimuli excite peripheral 
terminals of specialized primary afferent neurons called nociceptors (Woolf, 2000). There are 
two types of primary afferent nociceptors, myelinated A-delta mechanosensitive and 
unmyelinated C-fiber Polymodal (thermal, mechanical, chemical) nociceptors (Price & 
Dubner, 1977). A-beta mechanosensitive afferent stimuli do not evoke pain in humans, even 
at high intensity.  
 A-delta afferents conduct 1st pain, which is an immediate, sharp, pricking pain at 3-30 
meters per second (Willis, 1985; Price, 1972). C-fiber afferents conduct 2nd pain (1-1.5 sec 
later), which is a burning or throbbing type of pain at a much slower .5 to 2.0 meters per 
second (Price, 1972; Willis, 1985). There are three types of A-delta nociceptive afferents: 1) 
mechanical receptors high thresholds, and type 1 and type 2 mechano-thermal nociceptive 
afferents. Unmyelinated C-polymodal nociceptive afferents outnumber myelinated A-delta 
nociceptors, 3:1 (Price & Dubner, 1977), but in primate limbs, more than 90 % of cutaneous 
nociceptors are C-fiber polymodal neurons. 
Nociceptive neurons elicit a variety of responses from the central nervous system 
including spinal cord withdrawal reflexes, autonomic and neuroendocrine responses, as well 
as behavioral consequences of general alertness, arousal, and orientation (Palmgreen et al., 
2002). Secondary, or spinal nociception is primarily conducted by wide-dynamic-range 
neurons and some nociceptive specific neurons. Wide dynamic range neurons can detect 
temperature changes from 0.2 to 0.3 degrees in the painful range, from 45 to 510 Celsius (C), 
which nociceptive specific neurons cannot. Nociceptive specific nociceptors conduct 1st pain, 
and 2) wide dynamic range neurons conduct heat, pinch, and cold sensations in response to 
2nd pain, C-fiber signaling (Price & Dubner, 1977). Most Lamina V neurons are wide 
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dynamic range neurons, which do not differentiate tissue of origin and represent the 
integration of all afferent input to the dorsal horn.  
Ascending Pathways from the Gut 
Visceral pain is poorly localized for several reasons: 1) visceral afferents communicate to 
several dorsal horn connections across a wide rostral-ventral segment of the spinal cord, 2) 
visceral nociceptors converge with somatic afferents at the dorsal horn, and 3) visceral 
information travels vagal pathways to the brainstem leading to contrasting properties in the 
signaling process. 
 Visceral nociceptors are located within the mucosa and muscle layers of the 
gastrointestinal tract. Most are non-myelinated C-polymodal neurons, which respond to 
mechanical, chemical, and thermal stimulation. Also in the mucosa are myelinated, A-delta 
fibers, which primarily respond to mechanical and thermal stimuli (Crowell et al., 2005). 
Stimuli initiate a signal in these first order neurons, which pass through the splanchnic nerve 
to the sympathetic nervous system, through the dorsal root ganglion up to the dorsal horn.  
Secondarily, post-synaptic nerves begin in the dorsal horn, traveling up the spinothalamic 
tract, which crosses contralaterally, and spinoreticular tract within the spinal cord. 
Spinoreticular tract signals then synapses with thalamic and reticular formation nuclei in the 
pons and medulla. Finally, third order neurons continue to the limbic system and frontal 
cortex. In a parallel fashion, signals traveling through the spinothalamic tract travel through 
the aqueductal gray area of the midbrain, to the thalamus, where third order neurons then 
communicate to the sensory-motor cortex.  
 First order neurons release glutamate, which initially activates non N-methyl-D-
aspartate (NMDA) receptors of the second order neurons. NMDA receptors are initially 
blocked by the presence of magnesium. Glutamate also triggers the release of peptides: 
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substance P, calcitonin gene-related peptide (CGRP), and neurokinen A, from the pre-
synaptic primary afferent terminal, which depolarizes the post-synaptic membrane removing 
the magnesium block and allowing calcium to enter NMDA receptors (Mayer et al., 1999). 
Intra-cellular calcium then combines with calmodulin to create protein kinase, which leads to 
nitric oxide oxidase. Nitric oxide acts either as an intracellular messenger depolarizing the 
cell or as a neurotransmitter which causes presynaptic release of the primary visceral afferent 
(Mayer et al., 1999).  
Descending Pathways 
Descending pain regulatory signals originate in the insula, thalamus, anterior cingulate, pre-
frontal cortex, amygdala, hypothalamus and periductal gray area. Descending signals travel 
through the reticular activating system to the dorsal horn in both inhibitory and facilitative 
pain modulation. There are multiple spinoreticular/reticulospinal loops on each side of the 
body that these pass information in both directions, and may be inhibitory or facilitatory. 
They connect the spinal cord to: the dorsolateral pontine tegmentum, the rostral ventral 
medulla, the dorsal medulla, the caudal medulla, and the lateral hypothalamus. Other 
descending pain modulating pathways include: the cerebral cortex connections to the nucleus 
gracilis and cuneatus, reticular formation, and the thalamus; the peri-aqueductal grey matter 
direct connections to the dorsal, or to the raphe nuclei of medulla, and then to dorsal horn; 
and the locus ceruleus connections to the dorsal horn. 
 The inhibitory pathway reduces nociception by releasing peptides and 
neurotransmitters that reduce the ascending pain signal. These include: serotonin and 
norepinephrine which activate the opioids, glycerine, gamma-aminobytric acid and 
cholecystokinen from interneurons to blunt the pain signal. The facilitative pathways release 
  9
additional glutamate, which increases NMDA receptor activation to increase pain signals 
(Mayer et al., 1999). 
Visceral Hyperalgesia in Irritable Bowel Syndrome 
Although visceral pain is the most common form of pain produced by disease, there has been 
far more research into the mechanisms for neurogenic or somatic pain (Cervero & Laird, 
2004). The amount of visceral pathology is often not associated with the intensity of the pain 
in visceral pain states. For example, colitis and gastrointestinal ulcerations are not associated 
with significant pain, but pain is the central feature in functional gastrointestinal disorders, 
such as; IBS, dyspepsia, post-cholosistectomy syndrome, interstitial cystitis, and functional 
chest pain (Mertz, 2003), which show demonstrable no pathology. Visceral pain can lead to 
two forms of hypersensitivity: 1) Somatic pain in dermatomes that converge at the same 
dorsal horn neuron as the visceral afferents (referred hyperalgesia), and 2) enhanced 
sensitivity of the same or nearby viscera (visceral hyperalgesia). Giamberardino et al. (2000) 
suggests that the source of these sensory alterations must be the central nervous system 
because they often originate in healthy tissues. Considerable research suggests that enhanced 
excitability of spinal cord neurons substantially contribute to for visceral hyperalgesic states 
(Garrison et al., 1992; Hummel et al., 1997; Roza et al., 1998). 
 Although the etiology of IBS is unknown, patients have been shown to have visceral 
hypersensitivity to gut distensions. In addition, dyspepsia or upper gastrointestinal pain occur 
comorbidly in up to 80 % of IBS patients (Agreus et al., 1995). Ritchie, et al. (1973) first 
demonstrated lower pain thresholds in response to balloon distensions in the bowel in IBS 
patients compared to controls. Since this pioneering investigation, many researchers have 
confirmed this finding (Whitehead et al., 1980; Bouin et al., 2004; Hobday et al., 2000; 
Kwan et al., 2004; Mertz et al., 1995; Steens et al., 2002). Visceral hyperalgesia has been 
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consistently shown to be present in the majority of patients with IBS and is considered to be 
a biologic marker for IBS (Mertz et al., 1995), (Chun et al., 1999).  
Somatic Hyperalgesia in Irritable Bowel Syndrome  
Early studies found IBS patients to have higher or similar pain thresholds (THR) or pain 
tolerance (TOL) to noxious somatic stimuli compared to healthy controls (Cook et al., 1987; 
Accarino et al., 1995; Rossel et al., 1999; Whitehead et al., 1990; Zighelboim et al., 1995). 
However, most, but not all (Chang et al., 2000), recent investigations have found significant 
somatic hyperalgesia in IBS patients (Bouin et al., 2001; Verne et al., 2000; Verne et al., 
2003c). These studies suggest the possibility of a central dysregulation in normal pain signal 
processing as a potential mechanism in the etiology of IBS pain (Verne & Price, 2002). 
 In addition, Rodriguez (2005) and Verne (2003b) demonstrated that somatic pain 
sensitization was not limited to afferents in the L4-L5 dermatome, and that there was not a 
sensitization gradient across three sites tested (face, arm, and leg). These results suggest that 
somatic hyperalgesia in IBS is not limited to areas of visceral/somatic convergence. 
Rodrigues (2005) suggested that spinal hyper-excitability is consistent with this wide 
distribution of somatic hyperalgesia. In addition, Verne and Price (2002) describe IBS s a 
common precipitant of central sensitization. 
Sensitization 
It is known that sensitization occurs in IBS patients after repeated rectal distensions, leading 
to hyperalgesia of the rectum (Whitehead & Palsson, 1998; McRoberts et al., 2001; 
Munakata et al., 1997b). Bouin (2002) has identified lowered rectal pain thresholds as a 
hallmark of IBS, stating, “Dysregulation in the neurobiology of visceral afferents and pain 
sensitivity control (inhibition) is believed to explain IBS symptoms. It is not known whether 
this is due to peripheral, to central sensitization, or both.  
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Peripheral sensitization occurs when polymodal C-fiber nociceptors and A-fiber 
mechanonociceptors increase their sensitivity after repeated noxious stimulation which is 
unique to the nociceptive system. Sensitization results in a decreased threshold, an increased 
response to supra-threshold stimuli, and spontaneous activity. Inflammatory mediators such 
as prostaglandin’s, bradykinin, and adenosine triphosphate, sensitize primary afferents, 
especially C-fiber polymodal receptors, as well as recruit silent nociceptors. Recently, 
however, non-inflammatory mediators, such as glycerol sensitase, glutamate, and trypsin 
(released by stress) have been shown to trigger visceral pain and lower mechanical 
stimulation thresholds (Bueno & Fioramonti, 2002). The idea of an “inflammatory soup” 
may explain why medications with a variety of mechanisms of action have shown only 
partial benefit in treating IBS (Kirkup et al., 2001).  
 Central sensitization is the facilitation of central nervous system nociceptive neurons 
triggered by peripheral injury or nociceptive input from C-fibers (Woolf & Wall, 1986). It is 
characterized by reduced stimulation thresholds, an expansion of receptive fields, and an 
increase in background activity of spinal neurons. Strong or prolonged primary nociception 
causes plasticity leading to increased synaptic strength between the nociceptors and spinal 
neurons, so that smaller signals trigger pain (Woolf & Wall, 1986).  Woolf (2004) suggested 
that chronic pain conditions like IBS and Fibromyalgia may be due to central sensitization. 
Peripheral or Central Sensitization in Irritable Bowel Syndrome 
The exact cause of visceral hyperalgesia in IBS patients is not known (Delvaux et al., 2004). 
Gastric hypersensitivity could be due to local or central mechanisms following an event 
(Gebhart et al., 2002). Munakata et al. (1997a) reported that repeated stimulation of sigmoid 
splanchnic afferents led to central sensitization manifested as hyperalgesia and 
viscerosomatic referral during rectal distensions and to spontaneous rectosigmoid 
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hyperalgesia in the absence of applied stimuli, concluding that repetitive sigmoid 
contractions may induce rectosigmoid hyperalgesia in IBS.  
 Visceral hyperalgesia, seen in IBS patients, may be due to dysregulation of inhibitory 
or facilitative central processes, or from peripheral dysregulation, or some combination of 
these. Recent investigations suggest that chronic pain may be primarily the result of central 
sensitization. Lembo et al. (1994) reported that lidocaine in the rectum did not affect 
hypersensitivity in IBS patients, indicating lumbarsplanchnic pathways are involved in 
visceral hypersensitivity. Lembo et al. (2000) also found that IBS patients may have a 
diminished central release of endogenous opioids in response to visceral stimuli, based on 
their response to Fentanyl.  
 On the other hand, Vase et al. (2003) showed hyperalgesia was due to either spinal or 
peripheral influences, but not brain function, after local anesthesia of the rectum reversed 
hyperalgesia. Local lidocaine reversed hyperalgesia in the rectum, suggesting that central 
sensitization is maintained by tonic stimulation from rectum or colon (Verne et al., 2003b). 
Chey et al. (1995) found that Octreotide reduced rectal perception of electrical stimuli and 
suggested that this was associated with inhibited cerebral and spinal evoked potentials 
indicating an effect on spinal afferent pathways. In a study evaluating brain function in 
response to a non-visceral stimulus, Bloomhoff et al. (2000) found subjects with IBS to show 
hyper-reactivity in forebrain event-related potentials to auditory stimuli. The authors 
observed that aberrant brain functioning in response to non-visceral stimuli in their 
investigation, as well as to visceral stimuli in many previous studies, might indicate that 
aberrant central processing may be an aspect of IBS.   
In an animal model, Miranda et al. (2004) demonstrated convergence of visceral and 
somatic nociception by sensitizing gastrointestinal neurons using somatic pain stimuli. The 
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authors report that ionotropic glutamate receptors in the spinal cord are involved in 
sensitizing neurons that are sensitive to colorectal distension, concluding that “Sensitization 
occurs at the spinal level and is independent of supraspinal influences”. Peles, Miranda, and 
colleagues (Peles et al., 2004) then demonstrated that nociceptive somatic stimuli sensitized 
viscero-somatic convergent spinal neurons that respond to rectal distensions, and that a 
selective NMDA antagonist and an α-amino-3-hydroxy-5-methylisoxazole-4- propionic acid 
antagonist significantly attenuated the sensitized response to rectal distension in both intact 
and spinalized animal (Peles et al., 2004) 
Convergence was also demonstrated in a human model by Coffin and colleagues 
(2004) by testing the effects of rectal distensions on the somatic nociceptive reflex (RIII), 
which is an objective index of spinal nociceptive processes. IBS subjects were shown to have 
hyper-excitability of spinal nociceptive processes, when rapid rectal distensions reduced 
inhibitions of the somatic reflex RIII  seen on electromyography. Slow-ramp distensions also 
facilitated RIII reflex in IBS subjects (Coffin et al., 2004; Roza et al., 1998). 
Al-Chaer and colleagues (2000) developed an animal model of IBS and demonstrated 
visceral and somatic hyperalgesia in adult rats after subjecting them to rectal mustard oil as 
neonates demonstrating that increased wide dynamic range  neuronal activity was involved in 
both visceral and cutaneous hyperalgesia. Kawasaki and Al-Chaer (2003) found increased 
firing of somatic neurons after colorectal distension and vice-versa demonstrating 
convergence of visceral and somatic afferents at shared dorsal horn sites. In another 
demonstration of central viscerosomatic convergence, electrical stimulation of the leg 
facilitated visceral hyperalgesia, which was then blocked by ionotropic glutamate receptor 
antagonists administered to the lower spinal cord (Miranda et al., 2004). Willert et al. (2004) 
prevented and then reversed esophageal hypersensitivity in the proximal esophagus induced 
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by acid infusion in the distal esophagus by administering ketamine, an NMDA antagonist, 
indicating central sensitization as a mechanism in visceral hypersensitivity.  
Roza and colleagues (1998) identified changes in spinal neurons following 
nociceptive stimuli to the ureter of rats leading to visceral hyperalgesia. Further they found 
that continued noxious visceral input following induced visceral hyperalgesia  created 
changes in the dorsal horn neurons that could not be explained by a generalized excitability 
and suggested that this central hyperalgesic state depends on alterations in both central 
inhibitory and facilitative activity. 
In a magnetic resonance imaging (MRI) study, Verne et al. (2003b) found that both, 
visceral and cutaneous hyperalgesia was accompanied by increased activity in all levels of 
somatosensory afferent processing in the brain and concluded that hyperalgesia was due to 
increased afferent processing (which could include disinhibition) ascending to the brain and 
not due to selective increased activity at higher cortical levels (limbic and prefrontal areas). 
Verne et al. (2003b) also reported that MRI activity was not different (comparing IBS 
patients to healthy controls) during both, rectal noxious stimuli or during cutaneous noxious 
stimuli, leading the authors to conclude that the difference in pain ratings between IBS and 
healthy controls must be due to afferent signaling from the spinal cord or periphery. These 
findings are consistent with the idea that mechanisms involved in visceral and cutaneous 
hyperalgesia, at least in part, occur at the spinal level. Finally, in a review of visceral 
hyperalgesia studies, Verne and Price (2002) suggested that the frequency of extra-intestinal 
symptoms that are commonly seen in patients with IBS suggests a central hyperalgesic state.  
 Normal processing of noxious stimuli is complex, as it involves multiple central 
modulating systems that influence the pain signal before it reaches the thalamus. These 
include; ascending facilitation of nociception and descending modulation of these signals 
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which can be facilitative or inhibitory. Repetitive or intense noxious stimuli can result in 
sensitization of these pathways, both peripherally and centrally. Psychophysical 
investigations into abnormalities in pain processing in patients with chronic pain conditions 
have focused on afferent measures of temporal summation, and efferent DNIC effects.  
Temporal Summation 
Investigations to explore dysregulation of central pain mechanisms in chronic pain patients 
have focused on identifying exaggerations in temporal summation and deficits in DNIC. 
Temporal summation describes an increase in pain sensitivity in response to the ‘wind-up’ of 
second-order neurons, primarily in the dorsal horn. Wind-up is the increase in magnitude of 
second order nociceptive neurons in response to repetitive, brief, noxious stimuli (< .33 Hz) 
(Staud & Rodriguez, 2006) applied to C-fiber primary nociceptive afferents (Herrero et al., 
2000; Mendell, 1966). It is consistent and very reproducible (Herrero et al., 2000). Even non-
painful gut perception depends on temporal and spatial summation (Serra et al., 1998). This 
allows for stimuli that are not normally perceived to achieve conscious sensation. If a 
noxious stimulus arrives at the synapse in the dorsal horn more frequently than once every 
three seconds, the post-synaptic electrical discharge becomes more prolonged, which  results 
in an increase in the severity of the pain. Temporal summation is the psychophysical increase 
in pain sensitivity of the wind-up phenomenon (Ren, 1994). 
Although wind-up is exclusively evoked by unmyelinated afferent C-fibers under 
normal conditions, it is not a property of peripheral C-fibers, but is a property of the central 
synapses of these fibers with post-synaptic spinal wide-dynamic range neurons and to a 
lesser extent nociceptive specific (NS) neurons and as such, is exclusively a central 
phenomenon (Price et al., 1977). Primary A-delta and C-fiber afferents do not temporally 
summate, but actually are progressively suppressed. Adaptation of A-delta and C-fibers to 
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repeated brief heat suggests that wind-up must be a central phenomenon. Further, wind-up is 
shown to be a central phenomenon because C-fibers show a reduction in response amplitude 
and action potential (Price & Dubner, 1977) and because NMDA antagonists reduce it. 
Neuropathic pain has been alleviated by NMDA antagonists (Backonja et al., 1994; Eide et 
al., 1995); Felsby, 1995; Krictensen, 1992; Mathisen 1995). WIND-UP may underlie a 
continuation of pain from prolonged nociception despite a reduction in their number of action 
potentials in afferent C-fibers (Price, 1972; Price & Dubner, 1977). 
Wind-up is primarily the result of increases in the neurotransmitters, glutamate and 
aspartate and the neuromodulator, substance P, in the synapse between the C-polymodal 
primary afferents and dorsal horn neurons (Xu et al., 1992). These neurotransmitters activate 
NMDA receptors and neurokinen-1 receptors leading to prolonged depolarization of dorsal 
horn neurons. This wind-up phenomenon reflects a sensitization in the dorsal horn which 
leads to hyperalgesia (Price, 1999). Wind-up causes dorsal horn neurons to remain partially 
depolarized, which may cause spontaneous firing, hyper-responsiveness to weaker somatic 
stimuli. This leads to expansion and increased sensitization of the receptive fields (Li et al., 
1999). 
Wind-up can lead to spatial summation (of mechanosensitive A-delta afferents, but 
not heat sensitive C-fibers by expanding the receptive fields leading to recruitment of more 
dorsal horn neurons. Repetitive noxious stimulation of C-fibers leads to prolonged discharge 
of dorsal horn neurons. If wind-up is perpetuated beyond several minutes this can lead to 
long-term potentiation. This long lasting increase in the efficacy of synaptic transmission can 
last from one hour to several months Aziz (2000). Wind-up is believed to be instrumental in 
the creation or maintenance of chronic pain (Price, 1991).  
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Wind-up is usually tested using noxious phasic heat stimuli (Maixner et al., 1998; 
Staud et al., 2001; Staud et al., 2003) with increases in pain ratings indicating increases in 
temporal summation. While numerous studies have demonstrated enhanced temporal 
summation in somatic pain conditions, and wind-up of visceral afferents have been 
repeatedly demonstrated in animal models, only one, recent investigation has explored 
temporal summation using visceral noxious stimuli in human subjects (Sarkar et al., 2006). 
Sarkar and colleagues (Sarkar et al., 2006) demonstrated enhanced temporal summation to 
visceral electrical stimulation of the upper esophagus after inducing central sensitization 
using acid infusion to the lower esophagus in the first human model of visceral temporal 
summation. This mechanism has yet to be explored in patients with IBS. 
Diffuse Noxious Inhibitory Controls 
Counter-irritation has been known to decrease pain for centuries (Price, 1999), including 
references from Hippocrates stating that a stronger pain inhibits a weaker pain. This counter-
irritation phenomenon is called Diffuse Noxious Inhibitory Controls (DNIC). DINC 
mechanisms act like a barrier to prevent the spread of pain and keep it bearable (Pielsticker et 
al., 2005) by providing a tonic inhibitory influence. The benefits of DNIC are evident in 
dangerous circumstances, such as when in battle, during injury, and even during sports 
activities (Tracey, 2004) . 
 Deficits in DNIC are believed to play an important role in geriatric and chronic pain 
(Edwards et al., 2003a). DNIC occurs when wide dynamic range neurons in the dorsal horn 
of the spinal cord (nociceptive specific neurons are not affected by this type of control) are 
substantially inhibited by a second nociceptive stimulus administered anywhere in the body 
distinct from their excitatory receptive fields (Le et al., 1992). In normal conditions, these 
inhibitions can be triggered only by nociceptive conditioning stimulus (CS) from A-delta- or 
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C-peripheral fibers. The inhibitions are very potent, affecting all of the activities of the wide 
dynamic range neurons. 
 Testing DNIC requires administering phasic, noxious, test stimulus (TS), prior to and, 
during administering tonic, noxious, CS, typically, ischemic, cold pressure, or noxious heat 
pain, heteroptopically (Guieu et al., 1994; Kosek & Ordeberg, 2000b) (Lautenbacher & 
Rollman, 1997; Staud et al., 2003; Edwards et al., 2003a), however, some investigators have 
used tonic CS with a slow-ramp increases in temperature to identify threshold and tolerance 
levels (Sigurdsson, 1994). The term “diffuse” is derived form heterotopic inhibition, as 
opposed to homotopic inhibition, as in transcutaneous nerve stimulation (TNS). The 
difference between the pain that is experienced with the first phasic pain stimuli, without the 
conditioning stimulus, and with the second phasic stimuli during the concurrent tonic pain is 
described as the DNIC effect.  
 Dysregulation of pain modulation due to deficient DNIC is believed to play an 
important role in chronic pain conditions like Fibromyalgia (Lautenbacher & Rollman, 1997; 
Staud et al., 2003; Kosek & Hansson, 1997), TMD disorders (Sigurdsson & Maixner, 1994; 
Kashima et al., 1999; Maixner et al., 1997), osteoarthritis (Kosek & Ordeberg, 2000a), 
headache (Sandrini et al., 2006), and low back pain (Peters et al., 1992), but not all 
(Johannesson et al., 2006; Leffler et al., 2002a; Leffler et al., 2002b), leading experts to 
conclude that this central alteration in pain signaling may be important in the onset or 
worsening of symptoms. In these subjects, DNIC was shown to be absent or significantly 
diminished compared to controls. Lautenbacher (1997) showed that concurrent painful tonic 
thermal stimuli induced DNIC to electrical and heat pain in controls, but not in Fibromyalgia 
subjects (at non-painful sites). The protection offered by properly functioning DNIC appears 
to be lacking in these Fibromyalgia patients. According to Lautenbacher, the nature of 
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Fibromyalgia, or any chronic pain condition, points to a deficient DNIC process reflecting 
decrements in endogenous analgesic systems.  
 In all but one DNIC investigation of chronic pain conditions that are reported in the 
literature (Wilder-Smith et al., 2004), DNIC was tested using phasic noxious TS, including; 
electrical (Lautenbacher & Rollman, 1997; Pielsticker et al., 2005; Sandrini et al., 2006), heat 
(Maixner et al., 1995; Staud et al., 2003), and pressure (Kosek & Hansson, 1997) stimuli, 
with noxious tonic stimuli including: ischemic pain (Kashima et al., 1999; Kosek & Hansson, 
1997; Kosek & Ordeberg, 2000a; Maixner et al., 1995), hot (Staud et al., 2003) or cold water 
submersion of the hand or foot (Johannesson et al., 2006; Sandrini et al., 2006), or tonic heat 
thermode contact (Lautenbacher & Rollman, 1997; Pielsticker et al., 2005) as the CS. DNIC 
has also been tested in geriatric populations using heat (Edwards et al., 2003a; Washington et 
al., 2000), and electrical TS (Washington et al., 2000) and cold water submersion as CS 
(Edwards et al., 2003a; Washington et al., 2000) and found elderly to have deficient DNIC. 
 In the only study to investigate DNIC mechanisms in IBS patients  Wilder-Smith 
(2004) demonstrated significant differences in fMRI, in brain centers known to control 
autonomic, emotion, and descending modulatory responses to pain in IBS subjects compared 
to controls (Wilder-Smith et al., 2004). These changes corresponded to a compromised DNIC 
effect in visceral pain ratings from rectal distensions, before and during the administration of 
a conditioning (foot in ice water) stimulus.  
 In the Wilder-Smith study (2004) as well as several other DNIC investigations  
changes in average pain ratings (APR) during heterotopic counter-irritation, compared to no 
counter-irritation protocols were used as a measure of the DNIC effect (Edwards et al., 
2003b; Price & McHaffie, 1988; Staud et al., 2001), and changes in maximum pain ratings 
(MPR) during counter-irritation (Edwards et al., 2003b; Staud et al., 2001). Still others 
  20
compared test stimulus threshold (THR) or tolerance (TOL) values during counter-irritation 
compared to no counter-irritation conditions (Kashima et al., 1999; Kosek & Hansson, 1997; 
Kosek & Ordeberg, 2000b; Lautenbacher & Rollman, 1997; Maixner et al., 1995). 
 This investigation tested DNIC effects for heat pain THR and TOL during slow-ramp 
ascending method of limits paradigm, as well as for APR and MPR during phasic heat pain 
TS. In addition, a second conditioning stimulus that was not noxious in nature (neutral 
temperature water hand submersion) was include to attempt to isolate non-specific effects, 
such as distraction, that is known to play a role in the results of DNIC investigations. This 
strategy has been used by others (Edwards et al., 2003a; Sigurdsson & Maixner, 1994; Roby-
Brami et al., 1987), however, these investigators simply identified a lack of significant group 
differences in DNIC during the non-noxious CS that was seen in the noxious conditioning 
stimuli condition. Edwards and colleagues (Edwards et al., 2003b) improved on this concept 
in a post-hoc analysis by subtracting the change in pain ratings that occurred during non-
noxious conditioning from the DNIC effect found in the noxious conditioning protocol to 
yield a “controlled  measure of the degree to which thermal pain ratings change as a function 
of heterotopic cold pain”. This is an elegant way to remove non-specific effects from the 
change score in pain ratings that have nothing to due with the physiological effects of 
counter-irritation. 
Summary and Goals 
IBS is a complex disorder of unknown etiology. Research into the pathophysiology of IBS 
over the last decade has demonstrated the involvement of many factors contributing to IBS 
symptoms. Psychological, hormonal, immunological, genetic, cardiovascular, and autonomic 
nervous system factors, as well as peripheral and central sensitization of pain signals are 
believed to be involved in the etiology and/or maintenance of IBS. Visceral hyperalgesia is 
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consistently observed in IBS patients; however, recent investigations have found evidence of 
somatic hyperalgesia, not seen in earlier studies. This new data suggests the possibility that 
IBS patients may suffer from a global dysregulation in central pain processing.  
There is increasing interest in research in central nervous system processes, in both 
somatic and visceral pain (Tracey, 2004). There is considerable evidence suggesting that 
central sensitization is likely to play a major role in IBS pain. Psychophysical investigations 
into abnormalities in central pain processing have been observed in TMD and FMS patients, 
both of which have significant comorbidity with IBS. Whitehead and colleagues (2002) 
reported that as many as 77% of IBS patients also suffer from FMS and 64 % of IBS also 
suffer from TMD (Whitehead et al., 2002; Veale et al., 1991).  Veale et al. (1991) also 
reported that approximately 70% of FMS patients have chronic visceral pain. It seems likely 
that the central dysregulation in central pain processing seen in FMS and TMD patients may 
also be important in the onset or worsening of symptoms in IBS.  
 Investigations into central pain dysregulation in IBS may lead to improvements in 
diagnosis, and ultimately, to novel therapies for patients with IBS. The primary objective of 
the proposed investigation is to explore the role of central sensitization in IBS pain by 
assessing both efferent (DNIC) and afferent (temporal summation) central modulation of 








Potential subjects were recruited from the UNC Gastroenterology Division of the Department 
of Medicine (IBS) and through university-wide email and flyer advertisements (IBS and 
healthy controls) and screened by telephone interview to confirm that they met inclusion 
criteria.  
Inclusion: Subjects were pre-menopausal women, 18 years of age and older. IBS subjects met 
Rome II criteria (Drossman et al., 2000) for IBS and were currently suffering from painful 
symptoms of IBS.   
Exclusions:  Exclusionary criteria included the following: menopause, pregnancy or nursing, 
major clinical depression or anxiety disorder, hypertension, history of abnormal 
electrocardiogram, heart disease, kidney disease, diabetes, seizures, asthma, or thyroid 
disorder. Individuals taking analgesics, narcotics, or antidepressants were excluded from 
participation. Other medications were evaluated on a case-by-case basis. Healthy subjects did 
not have a history of any chronic pain conditions. 
  In order to control for non-specific effects unrelated to central pain regulatory 
mechanisms, several controls were instituted regarding subject selection and testing 
protocols. In addition to excluding males and post-menopausal females, subjects were 
scheduled for their visit during the follicular phase of their menstrual cycle (days 4-8) to 
control for possible gonadal hormone influences on pain perception. To minimize 
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sympathetic nervous system influences on pain perception, all subjects were instructed to 
refrain from consuming caffeine and nicotine for at least two hours prior to testing and all 
subjects were tested at approximately the same time in the afternoon to control for 
fluctuations in cortisol. Attempts were made to minimize psychological influences on pain 
perception by excluding individuals with an anxiety or depressive disorder. In addition, a 
battery of questionnaires to identify group differences in mood, perceived stress, and stress 
coping strategies were administered and significant group differences were included as 
covariates in the appropriate statistical analyses. It is well known that distraction plays a role 
in psychophysical investigations that include counter-irritation such as DNIC. To minimize 
these effects, a control condition, providing the same sensory input, except for nociception, 
was employed as the “counter-irritation” stimulus.  
 This investigation was approved by the University of North Carolina Medical Internal 
Review Board (05-MED-841). This investigation lasted approximately six months. Each 
subject’s participation lasted from two to two and one half hours, for a single visit. Each 
subject was paid $35 for completing the study. Following a review of the informed consent 
form, participating subjects were asked to complete several questionnaires. 
Outcome Measures  
Psychological Measures 
Questionnaires were used to identify the basic demographic characteristics of all subjects and 
to provide a standardized psychosocial evaluation in addition to acquiring information about 
the participant’s health history and current pain (See Appendix A). Demographic data and 
health history were acquired by the Demographic/medical history questionnaire (Levy et al., 
2000a). Psychosocial assessment covered four major areas: cognitive-behavioral adjustment 
to pain, general psychological status, pain coping/pain responsiveness, and perceived levels 
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of stress. Characterization of current clinical pain was obtained with the Irritable Bowel 
Syndrome Severity (Francis et al., 1997) and the Physical Symptoms Questionnaire (Palsson 
et al., 2002). Psychological status was measured with the State-Trait Anxiety Inventory 
(Spielberger et al., 1983), the Anger Expression Inventory (Spielberger et al., 1995), and the 
Beck Depression Inventory (Beck, 1961). The Perceived Stress Scale (Cohen et al., 1983) 
measured recent exposure and responses to stress and pain coping style was assessed by the 
Catastrophizing subscale of the Coping Strategies Questionnaire (CSQ) (Hirsh et al., 2006).  
 Following completion of the questionnaires, all subjects were given a brief exposure 
to the heat stimuli apparatus and the ice water conditioning stimulus in order to minimize 
apprehension regarding the TS. This consisted of a practice trial for each of the three heat 
pain testing procedures (THR, TOL, and phasic heat pain stimuli) and a brief exposure to the 
CS, by submerging their right hand in 120 C water for approximately 10 seconds.  
Sympathetic Nervous System Measures 
After the subject’s height and weight were acquired, the subjects right arm was instrumented 
with heart rate and blood pressure monitors (Acutracker, Suntech Instruments). After a 10-
minute rest, baseline blood pressure and heart rate were acquired as baseline measures. 
Immediately after each pain testing protocol heart rate and blood pressure were reacquired.  
General Pain Sensitivity Measures 
1) Pain Threshold (THR) was the temperature at which a non-painful stimulus first 
became painful in an ascending method of limits paradigm. 
2) Pain Tolerance (TOL) was the temperature at which a stimulus reached the maximum 
temperature that an individual was able or willing to tolerate in an ascending method 
of limits paradigm. 
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3) Average Pain Rating (APR) (Edwards et al., 2003b) was a measure of the average  
pain ratings given during the series of noxious phasic stimuli on a 0 to 100 scale, with 
0 representing no pain, and 100 representing the most intense pain imaginable. 
4) Maximum Pain rating (MPR)(Staud et al., 2001) (Edwards et al., 2003b) was the 
highest pain rating given during the phasic noxious stimulus series on a 0 to 100 
scale, with 0 representing no pain, and 100 representing the most intense pain 
imaginable. 
5) Water Pain Ratings (WPR) were acquired on a 0 to 100 scale, with 0 representing no 
pain, and 100 representing the most intense pain imaginable, immediately after the 
completion of the administration of the heat stimulus, but prior to removal of their 
other hand from the water.  
Measures of Central Pain Modulation 
1) Temporal Summation was assessed using two measures a) the rate of rise 
(RR)(Bhalang et al., 2005), or the slope of the least squares regression line of pain 
ratings during the first six phasic noxious stimuli provided at a rate of once every 
three seconds on a 0 to 100 scale (temporal summation is known to plateau after 5-6 
stimuli in a train), and, b) Delta (Bhalang et al., 2005; Edwards, 2005),  which 
subtracts the first pain rating on a 0 to 100 scale, with 0 representing no pain, and 
100 representing the most intense pain imaginable, from the peak pain rating across 
phasic stimuli trains yielding the degree of increase during the series. 
2) DNIC was assessed using two different test stimulus conditions during two different 
types of CS. First, changes in measures of THR and TOL during a slow-ramp heat TS 
(Edwards et al., 2003b; Sigurdsson & Maixner, 1994) were acquired with CS at 120 C, 
and again using 320 C circulating water. Second, DNIC effects were acquired during 
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phasic noxious heat stimuli for APR and MPR without counter-irritation to these 
same measures during CS at 120 C, and again using 320 C circulating water (Staud et 
al., 2001). 
3) The DNIC effect on Temporal summation was assessed by comparing a) the 
difference in RR without counter-irritation to the RR measure during counter-
irritation (using both 120C and 320 C as a conditioning stimulus), and b) by comparing 
the difference in Delta without counter-irritation to the Delta measure during counter-
irritation (using both 120 C and 320C as a conditioning stimulus). 
Heat pain threshold and tolerance temperatures were assessed at three locations (then 
averaged) on the glabrous surface of the left forearm for all subjects. Temporal summation 
and DNIC were assessed at two positions, which were counter-balanced between subjects on 
the palmar surface of the left hand at two different temperatures, one being established just 
above the individual tolerance temperatures acquired from the previous test and one set at 500 
C for all subjects. DNIC was assessed using the slow-ramp test stimulus, as well as the 
phasic heat pain stimuli at both thermode temperatures using two different conditioning 
water temperatures, which were counter-balanced between subjects, one being held constant 
at a noxious temperature (120 C) and one held constant at a neutral temperature (320 C) to 
control for non-specific effects. Finally, the effect of DNIC on temporal summation was 
assessed at both thermode temperatures and using both water temperatures. The subject’s 
participation included a total of 18 minutes of actual testing, alternating with 36 minutes of 
rest periods, in addition to 45-60 minutes to complete a review of the informed consent form 




Pain Testing Protocols 
Pain Threshold and Pain Tolerance  
Session B1: Heat pain thresholds (THR) were obtained using a controlled thermal device 
held in continuous contact with the skin of the glabrous surface of the left forearm in a slow-
ramp protocol for each subject (Medoc Medical Instruments Inc.). The thermal stimuli were 
delivered using a thermode (30 by 30-mm) contactor. Heat stimuli began at 380C and 
increased in 0.50 C/second increments in an ascending method of limits paradigm. Inter-trial 
thermode temperature returned to 380C. To ensure participant safety, a maximum temperature 
of 51°C  was used, which is 2°C below the maximum that is recommended to avoid tissue 
damage by the manufacturer, as well as previous investigators (Edwards et al., 2003a). 
Subjects rated the intensity of the thermal stimuli by clicking a mouse to establish pain 
thresholds. Subjects were told that they may discontinue the heat stimuli at any time by 
clicking on the mouse, which immediately discontinued the thermal stimuli, or by verbally 
requesting the session be stopped. Three trials, one centimeter apart, moving distally 
beginning one cm from the break in the elbow, and separated by 10 second rests, were 
performed and averaged for threshold (maximum duration of 30 seconds each). Blood 
pressure and heart rate were acquired immediately following the end of sensory testing. 
Differences in pain threshold were compared between groups. 
Session B2: Following a three-minute rest, heat pain tolerance (TOL) were obtained in the 
same manner as THR temperatures except that subjects were instructed to identify the 
maximum heat pain that the were able or willing to tolerate by clicking the mouse which 
discontinued the heat stimuli (maximum duration of one minute each). 
Temporal Summation  
Temporal summation was assessed using two different thermode temperatures.  
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Session W1: Following a three-minute rest, the first temporal summation protocol was 
performed. During this procedure, the peak temperature of the thermode remained constant, 
at the mean pain tolerance temperature (rounded up to the nearest whole number) established 
in Session B2 for the duration of the temporal summation protocol. Baseline temperatures 
were 100C below individualized peak temperatures. Each heat pulse was delivered at a rate of 
one pulse every three seconds to ensure temporal summation (maximum 8 trials). Subjects 
rated the intensity of the pain from the thermal stimuli on a 0 to 100 scale, with 0 
representing no pain, and 100 representing the most intense pain imaginable. Subjects were 
informed that the procedure would be terminated if they give a rating of 100 or verbally 
request that the stimuli be discontinued. Heart rate and blood pressure were reacquired 
immediately following the end of sensory testing. Differences in the RR (slope) from the first 
six pain ratings and in Delta (subtracting the first pain rating from highest pain rating) were 
compared between groups as measures of temporal summation.  
Session W2: Following a three-minute rest, a second temporal summation protocol was 
performed at a different site on the palm (order was also counter-balanced between subjects). 
During this procedure, the temperature of the thermode remained at 500 C for each pulse peak 
for the duration of the temporal summation protocol. As in session W1, subjects rated the 
intensity of the pain from the thermal stimuli on a 0 to 100 scale, and subjects were informed 
that the procedure would be terminated if they give a rating of 100 or verbally request that 
the stimuli be discontinued. Heart rate and blood pressure were acquired immediately 
following the end of sensory testing. Differences in the RR and in Delta were compared 




Diffuse Noxious Inhibitory Controls 
DNIC effects were assessed in two manners: 1) using TS in a slow ramp ascending method 
of limits for THR and TOL using 120 C (noxious) and again using 320C (non-noxious) CS 
(Sessions D1 - D4), and 2) using phasic TS at two different, but constant temperatures 
(individualized to TOL temperatures from session B2, and 50C) using the same two CS 
above (120C and 320 C) in separate tests (Sessions WD1 - WD4). 
Session D1: Following a three-minute rest, heat pain THR was obtained using the slow ramp 
administration of the test stimulus, as in sessions B1 (above), respectively, while a tonic 
conditioning stimulus was applied to the right hand. The conditioning stimulus for assessing 
DNIC was ice water submersion (120 C) of the right hand up to the wrist, in a circulating 
bath. Blood pressure and heart rate was acquired prior to, and immediately following the end 
of sensory testing. Changes in THR (temperatures) were compared between groups. 
Session D2: Following a three-minute rest, heat pain TOL was obtained using the slow ramp 
administration of the test stimulus, as in sessions B2 (above), respectively, while a tonic 
conditioning stimulus was applied to the right hand. The conditioning stimulus for assessing 
DNIC was ice water submersion (120 C) of the right hand up to the wrist, in a circulating 
bath. Blood pressure and heart rate was acquired prior to, and immediately following the end 
of sensory testing. Changes in TOL (temperatures) were compared between groups. 
Session D3: Following a three-minute rest, the protocol for D1 was duplicated except that the 
temperature of the water used for the conditioning stimulus was a neutral, non-noxious 
temperature (320 C) to control for non-specific effects. Changes in THR (temperatures) were 
compared between groups. 
Session D4: Following a three-minute rest, the protocol for D2 was duplicated except that the 
temperature of the water used for the conditioning stimulus was a neutral, non-noxious 
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temperature (320 C) to control for non-specific effects. Changes in TOL (temperatures) were 
compared between groups. Subjects were instructed to focus their attention of the slow-ramp 
heat pain test stimulus through the DNIC protocol and not on the conditioning stimulus. 
 To prevent order effects, the DNIC protocols using the two water temperatures as CS 
counter-irritation were counter-balanced. In addition, the position of the thermode for the 
tolerance temperature and 500 C thermode temperature was also counter-balanced at the base 
of the thumb and the heel of the hand for all phasic pain testing protocols. 
Session WD1: Following a three-minute rest, heat pulses were administered at the 
individualized temperature used in session W1, while a tonic conditioning stimulus was 
applied to the right hand. The conditioning stimulus for assessing DNIC was ice water 
submersion (120 C) of the right hand up to the wrist, in a circulating bath. Phasic heat pain 
testing commenced after the subject’s right hand was submerged in ice water for 20 seconds. 
The tonic noxious stimulation was delivered continuously to maintain a moderate level of 
pain during the assessment of phasic heat pain ratings. The duration of the DNIC protocols 
were less than 1 minute (24 seconds of phasic heat testing and 20 seconds of the conditioning 
stimulus prior to the initiation of the test stimulus). Subjects were instructed that they may 
stop the tonic cold pain or phasic heat stimuli at any time if the discomfort is greater than 
they wish to endure. Blood pressure and heart rate were acquired immediately following the 
DNIC testing. Changes in APR and MPR from baseline (session W1) to testing during 
counter-irritation (session WD1) were compared between groups. 
Session WD2: Following a three-minute rest, heat pulses were administered at peaks of 500 C 
for all subjects, while a tonic conditioning stimulus was applied to the right hand. The 
conditioning stimulus for assessing DNIC was ice water submersion (120 C) of the right hand 
up to the wrist, in a circulating bath. Phasic heat pain testing commenced after the subject’s 
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right hand was submerged in ice water for 20 seconds. The tonic noxious stimulation was 
delivered continuously to maintain a moderate level of pain during the assessment of phasic 
heat pain ratings. The duration was less than 1 minute of phasic heat testing, as in session 
WD1. Subjects were instructed that they may stop the tonic pain or phasic heat stimuli at any 
time if the discomfort is greater than they wish to endure. Blood pressure and heart rate were 
acquired immediately following the DNIC testing. Changes in APR and MPR from baseline 
(session W2) to testing during counter-irritation (session WD2) were compared between 
groups. 
Session WD3: Following a three-minute rest, the protocol for WD1 (thermode at tolerance 
temperatures) was duplicated except that the temperature of the water used for the 
conditioning stimulus was a neutral, non-noxious temperature (320 C) to control for non-
specific effects. Changes in APR and MPR from baseline (session W1) to testing during 
counter-irritation (session WD3) were compared between groups. 
Session WD4: Following a three-minute rest, the protocol for WD2 (thermode at 500 C) was 
duplicated except that the temperature of the water used for the conditioning stimulus was a 
neutral, non-noxious temperature (320 C) to control for non-specific effects. Changes in APR 
and MPR from baseline (session W2) to testing during counter-irritation (session WD4) were 
compared between groups. 
 To prevent order effects, the DNIC protocols using the two water temperatures as CS 
counter-irritation were counter-balanced. In addition, the position of the thermode for the 
tolerance temperature and 500 C thermode temperature was also counter-balanced at the base 
of the thumb and the heel of the hand for all phasic pain testing protocols. Subjects were 
instructed to focus their attention of the phasic heat pain test stimulus through the DNIC 
protocol and not on the conditioning stimulus.  
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The Effect of Diffuse Noxious Inhibitory Controls on Temporal Summation  
Changes in temporal summation measures, RR and Delta, during sessions W1 and WD1 
(thermode at individualized tolerance temperatures, conditioning stimulus at 120 C) were 
assessed as measures of the effect of DNIC on temporal summation. In addition, changes in 
RR and Delta during sessions W2 and WD2 (thermode at 500 C, conditioning stimulus at 120 
C) were assessed as measures of the effect of DNIC on temporal summation. 
 To control for non-specific effects these same measures of temporal summation (RR 
and Delta) were assessed comparing W1 and WD3 (thermode at individualized tolerance 
temperatures, conditioning stimulus at 320 C) as well as comparing RR and Delta during W2 
and WD4 (thermode at 500 C, conditioning stimulus at 320 C) sessions. Again, the order of 
the conditioning stimulus protocols was counter-balanced between subjects and subjects were 
instructed to focus their attention of the phasic heat pain test stimulus through the DNIC 
protocol and not on the conditioning stimulus.  
Data Analysis 
Significant differences between patient and control groups in endogenous pain mechanism 
measures have been demonstrated in comparable investigations of TMD (Kashima et al., 
1999; Maixner et al., 1997; Sigurdsson & Maixner, 1994), and FMS (Staud et al., 2001; 
Lautenbacher & Rollman, 1997; Kosek & Ordeberg, 2000b) using small to moderate total 
sample sizes ranging from 10 to 51 (mean sample size = 31). Thus, the sample size for this 
investigation was more than adequate to demonstrate significant group effects.  
 The first step in the data analyses was to calculate descriptive statistics and measures 
of the distribution of all the variables. Groups were compared by analysis of variance 
(ANOVA) with respect to all demographic variables. If there were significant differences, 
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these variables became covariates in subsequent analyses. Alpha was set at p<.05 for all 
analyses (SPSS, 15.0). 
Primary Outcome Measures of Central Pain Modulation  
Temporal Summation 
ANOVA was used to compare group differences in temporal summation measures (RR and 
Delta) at both thermode temperature settings (individualized thermode temperature and 500 
C).  
Diffuse Noxious Inhibitory Controls 
Separate Repeated-measures analysis of variance (ANOVA) were performed with Group as a 
between-subjects factor and Time (protocols including the conditioning stimulus vs. those 
without) for each DNIC measure: changes in THR, TOL, and changes in APR and MPR for 
both thermode temperature conditions (individualized thermode temperature and 500 C) 
during both counter-irritation conditions (120 C and 320 C water submersion of the other 
hand). 
 However, in order to control for non-specific effects, such as distraction, which is 
known to play a major role in DNIC effects, a Repeated-measures ANOVA was performed 
entering the APR for the non-noxious and for the noxious conditioning stimuli protocol for 
Time. This is precisely the same as comparing the difference in the DNIC effect during 120 C 
to the DNIC effect during 320 C CS. According to Edwards and colleagues, (2003b),  
 “This gives a controlled (i.e. effects of the neutral water temperature session are 
 subtracted) measure of the degree to which thermal pain ratings change, specifically 
 as a result of heterotopic cold pain and provides measures of the decrease in average 
 heat pain ratings during 120 C relative to 320 C CS.”  
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This analysis was performed on the DNIC measures to determine group differences for APR, 
MPR, THR, and TOL measures. 
Diffuse Noxious Inhibitory Controls Effect on Temporal Summation 
Repeated-measures analysis of variance (ANOVA) were performed for changes in each 
measures of temporal summation (RR and Delta) for both thermode temperature conditions 
(individualized thermode temperature and 500 C) and both CS (120 C and 320 C). 
Secondary Outcome Measures 
ANOVA was used to compare group differences for all General Pain Sensitivity Measures 
 (APR, MPR, THR, and TOL). In addition, ANOVA was used to compare group differences 
for all psychological measures (anxiety, depression, anger expression, perceived stress, and 
catastrophizing) and sympathetic nervous system outcome measures. ANOVAs were used to 
compare group changes in sympathetic nervous system activity (systolic blood pressure and 
heart rate). Significant differences between IBS and control subjects in sympathetic nervous 
system activity and psychological measures were used as covariates in ANCOVAs for 








Forty eight subjects were recruited for this investigation. This included 21 healthy controls 
(HC) and 27 patients with IBS. Five IBS patients also had another chronic pain condition (3 
with migraines, 2 with TMD). There were no significant differences (p > 0.05) between the 
IBS and HC groups on any demographic variables. Eighty-five % (IBS) and 81% (HC) of 
subjects were college graduates. Forty-eight % (IBS) and 29% (HC) of those were graduate 
students. Groups were age matched (HC = 28.5 years and IBS = 28.9 years). The groups 
mean Body Mass Index was also virtually the same (HC = 23.9 and IBS = 24.1). IBS patients 
included 25 Caucasian, one African American, and one Asian. Healthy controls included 14 
Caucasians, 3 African American, one Asian, two Native Americans, and one Sudanese.  
 IBS subjects reported a mean symptom severity score of 251.9 on the Irritable Bowel 
Severity Scale (Francis et al., 1997). This represents a moderate severity of IBS symptoms. 
This included five subjects who rated the symptoms as mild, thirteen as moderate and nine as 
severe. 
Secondary Outcome Measures  
Psychological Outcome Measures 
ANOVA demonstrated that IBS patients reported significantly greater stress than did HC 
(Table 4.1) as reflected in scores on the state anxiety index of the Spielberger State Trait 
Anxiety Index (p = 0.008), the anger-out subscale on the Anger expression Inventory (p = 
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0.039), and the Catastrophizing subscale of the CSQ (p = 0.005) and the Beck Depression 
Inventory (p = 0.026). 
 After controlling for psychological measures of IBS subjects having other chronic 
pain conditions, group differences remained significant for the state anxiety measure (p = 
0.006), the catastrophizing coping strategy (p = 0.01) and demonstrated a strong trend for the 
anger-out measure (p = 0.058). 
Sympathetic Nervous System Outcome Measures 
There were no group differences (p > 0.05) on any measures of sympathetic nervous system 
activity (systolic blood pressure and heart rate) either at baseline or after any of the pain 
testing protocols. In an addition there were no group differences (p > 0.05) in changes in 
systolic blood pressure and heart rate after any pain test. 
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___________________________________________________________________________ 
Questionnaires    Controls   IBS 
___________________________________________________________________________ 
State anxiety**    25.6 (1.6)   32.2 (1.7) 
Trait anxiety     29.4 (1.6)   33.6 (2.0) 
Depression*                             1.9 (1.1)     4.8 (.9) 
Anger expression                           42.9 (.75)   45.0 (.7) 
Anger-in expression    26.4 (.56)   25.3 (.57) 
Anger-out expression*   11.9 (.64)   13.6 (1.0) 
Perceived stress      16.9 (1.5)    21.5 (1.8) 
Catastrophizing**      1.4 (1.8)     2.0 (.17) 
Note: *p < 0.05, ** p < 0.01. 
Table 4.1 - Group mean (SEM) scores for all psychological questionnaires  
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General Pain Sensitivity Measures 
There were no group differences (p > 0.05) in any of the general pain sensitivity outcome 
measures for either thermode temperature, during baseline, or during the CS protocols in 
APR or MPR (Table 4.2). However, there were significant group differences for all of the 
DNIC measures (changes in APR and MPR from baseline to during the CS protocol) using 
noxious water temperature (120 C) as the conditioning stimulus and the 500 C thermode 
temperature as the test stimulus, but not when the water temperature was non-noxious (320 
C), or when the thermode temperature was less noxious (mean temperature 460C), based on 
individualized TOL temperatures from earlier testing. In addition, when significant group 
differences found in the psychological measures; state anxiety on the Spielberger State Trait 
Anxiety Index, the Beck Depression Inventory, Anger-out subscale of the Anger Expression 
Inventory, and the Catastrophizing subscale of the Coping Strategies Questionnaire, were 
entered as covariates in separate ANCOVAs for APR and MPR DNIC effects, only the 
Catastrophizing subscale of the CSQ had any effect on group differences, and only for one of 
the endogenous pain mechanism outcome measures (MPR, p = 0.071). 
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 __________________________________________________________________________ 
Protocols     Controls   IBS 
___________________________________________________________________________ 
Threshold     39.4 (.65)   39.6 (.69) 
Tolerance     45.9 (.63)   45.5 (.64) 
Maximum Pain Rating#   39.9 (4.7)   42.2 (4.3) 
Maximum Pain Rating^   55.5 (5.7)   54.3 (5.4) 
Average Pain Rating#    31.5 (4.1)   36.2 (3.9) 
Average Pain Rating^    47.6 (5.3)   47.5 (4.9) 
Water Pain Rating@    67.1 (4.9)   68.1 (5.2)  
Water Pain Rating$    58.6 (4.9)   64.6 (5.2) 
Water Pain Rating#    58.3 (4.3)   58.9 (4.9) 
Water Pain Rating^    55.5 (4.8)   57.4 (5.2) 
_________________________________________________________________________ 
Note: None of the group comparisons for means of the General Pain Sensitivity Measures 
were significant. All Water Pain Ratings were during 120 Celsius conditioning stimuli. # = 
individualized thermode temperatures, ^ = thermode at 500 Celsius. @ = pain threshold test, $ 
= pain tolerance test. 
Table 4.2 Group means (SEM) for all general pain sensitivity outcome measures. 
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There were no group differences (p > 0.05) on any of the general measures of heat pain 
including: pain threshold or pain tolerance temperatures, APR, or MPR. Nor were there any 
group differences (p > 0.05) in pain ratings due to water submersion of the right hand (mean 
H2O pain ratings, HC= 56.5, IBS = 57.5). 
 All APR, MPR, and H2O general pain sensitivity ratings were significantly correlated 
with each other (p < 0.01) and with THR and TOL scores (p < 0.05). All measures of DNIC 
are also significantly correlated with each other. However, none of the DNIC measures were 
associated with any of the general pain sensitivity measures. 
Primary Outcome Measures of Central Pain Modulation 
Temporal Summation 
Rate of Rise – No significant group differences (p > 0.05) were found in temporal 
summation (Table 4.3) for either thermode temperature setting (500 C or individualized 
temperatures). Using individualized thermode temperature setting, there was a trend 
(ANOVA, p =  0.051) showing IBS subjects to have a steeper increase (β = 0.68) in pain 
ratings, however HC did not demonstrate any temporal summation during this protocol, but 
in fact, showed a reduction in pain ratings across stimuli (β = -1.03). Slopes for the 500 C 
thermode setting were β = 1.68 for the IBS group and β = 1.06 for HC (ANOVA, p = 0.41). 
Delta – Similarly, no group differences (p > 0.05) were seen for either thermode temperature 
setting protocols when comparing increases in pain ratings from the initial stimuli to the 
highest pain rating in the train of phasic stimuli. 
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___________________________________________________________________________ 
Protocols     Controls         IBS 
___________________________________________________________________________ 
Rate of Rise#     -1.03 (.71)       .68 (.52) 
Rate of Rise^      1.06 (.6)     1.68 (.47) 
Delta#        7.5 (1.8)     9.5 (2.1)  
Delta^        13.7 (2.4)     13.7 (2.5)  
Note: None of the group comparisons for a Temporal Summation Rate of Rise (slopes), Delta 
values, or the DNIC effect (values not shown) on Rate of Rise or Delta were significant. 
# = individualized thermode temperatures, ^ = thermode at 500 Celsius. 
Table 4.3 - Group means (SEM) for Temporal Summation measures. 
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Diffuse Noxious Inhibitory Controls Effect on Temporal Summation – Using Repeated-
measures ANOVA, no significant group differences (p > 0.05) were found in the DNIC effect 
for either of the  temporal summation measures (RR and Delta) for either thermode 
temperature setting (500 C or individualized temperatures). 
Diffuse Noxious Inhibitory Controls 
Average Pain Rating -  With the phasic peak thermode temperature test stimulus at 500 C for 
all subjects and the conditioning stimulus of 120 C water, a Repeated Measures ANOVA 
demonstrated that there was a significant main effect of Time (indicating a DNIC effect 
across all subjects) [F = 30.4 (1,46), p < 0.001, η2 = .4. There was also a significant 
interaction effect (Figure 4.1) between Group X Time [phasic pain rating (APR) with and 
without the conditioning stimulus], indicating a deficit in the DNIC effect for IBS subjects [F 
= 6.97 (1, 46), p = 0.011, η2 = 0.13].  
 This interaction effect remained significant after controlling for changes in APR pain 
ratings from IBS patients who reporting having a second chronic pain condition [F = 4.85 (1, 
41) (p = 0.033). None of the psychological measures that demonstrated significant group 
differences were associated with APR scores or changes in APR scores during DNIC testing.
 Repeated-measures ANOVA found non-significant interaction effects (p > 0.05) in 
APR for the DNIC protocol using the individualized thermode temperature (mean thermode 
temperature for control group = 46.30 C and mean thermode temperature for the IBS group =  
46.00 C) while using 120 C circulating water as the conditioning stimulus (p = 0.35). There 
were also non-significant interaction effects for both protocols (test stimulus with the 
thermode at 500 C and at individualized thermode temperatures) using water temperature at 
320 C for the CS (p = 0.6 and p = 0.8, respectively). See Figure 4.2 for a comparison of DNIC 
effects during both CS temperatures with thermode at 500 C. Group differences in APR were 
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consistently larger for the control group in all but one instance (where they were equal). 
However, this does not reflect a DNIC effect, in that a non-noxious CS does not recruit DNIC 
mechanisms. This reduction in pain ratings during non-noxious conditioning stimuli reflects 
non-specific effects, including distraction. 
 After controlling for non-specific effects, the interaction effect demonstrated 
significantly greater DNIC effects (Figure 4.3) for HC on reduction in APR scores compared 
to IBS subjects [F = 11.04 (1, 46) p = 0.002) η2 = 0.19. Group differences in the DNIC effect 
score, based on percent reductions in APR scores were the same (p = 0.002). This provides a  
measure of the decrease in average heat pain ratings during 120 C relative to 320 C CS. Mean 
pain ratings for all water emersion protocols were 61.2 (3.4) for 120 C, and less than 1.0 
(0.46) for 320 C water emersion. There were no differences between groups for either water 
temperature pain rating. 
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Figure 4.1 Average Pain Ratings of the phasic test stimulus (thermode at 500 C). Reductions 
in pain ratings (DNIC effect) from no CS to Average Pain Ratings during the tonic CS at 120 
C, demonstrates compromised DNIC in IBS subjects compared to controls (p = 0.011). TS = 
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Figure 4.2 Reductions in Average pain Ratings of the phasic test stimulus (DNIC effect) 
during conditioning stimuli. Significant group differences in DNIC occurred only during 120 
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Figure 4.3 Group differences in the DNIC effect during noxious conditioning stimuli after 
removing non-specific effects from “counter-irritation” during neutral conditioning stimuli. 
APR = Average Pain rating, MPR = Maximum Pain Rating, IBS = Irritable Bowel Syndrome 
(p < 0.01 ANOVA).  














DNIC Effect After Removing Non-specific Effects
#Thermode=50°C, @Thermode at individual temperatures
Controls IBS
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Maximum Pain Rating -  With the phasic peak thermode temperature test stimulus at 500 C 
for all subjects and the conditioning stimulus of 120 C circulating water, a Repeated Measures 
ANOVA demonstrated that there was a significant main effect of Time, indicating a DNIC 
effect across all subjects [F = 35.8 (1, 46), p < 0.001, η2 = .44]. In addition, there was also a 
significant interaction effect (Figure 4.4) between Group X Time [phasic pain rating (MPR) 
with and without the conditioning stimulus], indicating a deficit in the DNIC effect for IBS 
subjects [F = 7.4 (1, 46), p = 0.009, η2 = 0.14].  
 This effect remained significant after controlling for MPR from IBS patients who 
reported having a second chronic pain condition [F = 5.0 (1, 41) (p = 0.032). The 
Catastrophizing subscale of the Coping Strategies Questionnaire and the State subscale of the 
Spielberger State Trait Anxiety Inventory were negatively associated with the DNIC effect 
for MPR (r = - 0.37, p = 0.01 and r = - 0.37, p = 0.01, respectively). After including these 
psychological variables scores as covariates in a Repeated-measures ANCOVA, group 
differences in MPR demonstrated a trend in favor of the control group (F = 2.24 (1, 44), p = 
0.14, η2 = 0.05].  As scores on the Catastrophizing subscale of the Coping Strategies 
Questionnaire increased, the DNIC effect, as reflected by reductions in MPR during the 120 C 
circulating water CS, were reduced. In addition to the significant negative association with 
catastrophizing, DNIC effects on MPR were negatively correlated with IBS symptom 
severity (r = - 0.31, p = 0.019), and with severity of co-morbid conditions (r = - 0.31, p = 
0.03, which suggests that elevations in catastrophizing and symptom severity may contribute 




 Repeated-measures ANOCOVA found non-significant interaction effects (p > 0.05) in 
changes in MPR for the DNIC protocol using the individualized thermode temperature (mean 
thermode temperature for control group = 46.30 C and mean thermode temperature for the 
IBS group =  46.00 C) using 120 C circulating water as the conditioning stimulus (p = 0.26). 
There were also non-significant interaction effects for both protocols (test stimulus with the 
thermode at 500 C and at individualized thermode temperatures) using water temperature at 
320 C for the CS. See Figure 4.5 for a comparison of DNIC effects during both CS 
temperatures with thermode at 500 C. Group differences in MPR tended to be larger for the 
control group in all but two instances (where they were equal). However, this does not 
indicate a DNIC effect, in that a non-noxious CS does not recruit DNIC mechanisms. 
 After controlling for non-specific effects (see Figure 4.3), the interaction effect 
continued to demonstrated significantly greater DNIC effects on reduction in MPR scores for 
HC compared to IBS subjects [F = 9.45 (1, 46) p = 0.003, η2 = 0.19]. Group differences in 
the DNIC effect based on percent reductions in MPR scores were the same (p = 0.003). This 




Figure 4.4 Maximum Pain Ratings of the phasic test stimulus (thermode at 500 C). 
Reductions in pain ratings (DNIC effect) from no CS to Maximum Pain Ratings during the 
tonic CS at 120 C, demonstrates compromised DNIC in IBS subjects compared to controls  
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Figure 4.5 Reductions in Maximum Pain Ratings of the phasic test stimulus (DNIC effect) 
during conditioning stimuli. Significant group differences in DNIC occurred only during 120 
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Threshold 
Although there were no group differences in the DNIC effect for pain Tolerance 
temperatures, a Repeated-measures ANOVA demonstrated that there was a significant main 
effect of Time (indicating a DNIC effect across all subjects) [F = 182.6 (1, 46), p < 0.001] 
during the 120 C conditioning stimulus (Figure 4.6) for Threshold. In addition, there was also 
a significant interaction effect) between Group X Time with and without the conditioning [F 
= 5.34 (1, 46), p = 0.025]. In addition, similar effects were seen for Threshold during the 320 
CS with significant group differences [F = 12.34 (1, 46), p  = 0.001]. See Figure 4.7 for a 
comparison of DNIC effects during both CS temperatures. These effects remained significant 
after controlling for Threshold temperatures from IBS patients who reporting having a 
second chronic pain condition [F = 5.0 (1, 41) (p = 0.032). 
 After controlling for non-specific effects (see Figure 4.3), there were virtually no 
changes in Threshold temperatures (1 to 2 percent) and no group differences. There were no 
interaction effects in the DNIC effect between groups for changes in TOL temperatures 
during either conditioning stimulus temperature. There were also no DNIC effects (less than 
1 percent) for TOL after controlling for non-specific effects. 
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Figure 4.6 Threshold temperatures (slow-ramp ascending method of limits). Significant 
group differences in increased pain threshold temperatures occurred during both noxious and 
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Figure 4.7 Increases in Pain Threshold temperatures (slow-ramp ascending method of limits) 
during conditioning stimuli (DNIC effect). Significant group differences in DNIC occurred 
during both noxious and non-noxious conditioning stimuli (p = 0.025, and p = 0.001, 
respectively). 































Summary of Results 
The primary outcome of the present investigation was that significant group differences in 
DNIC were found in APR, MPR and THR indicating deficits in DNIC for subjects with IBS 
compared to controls. These deficits remained unchanged after controlling for the effects of 
IBS subject who had a second chronic pain diagnosis, and after controlling for psychological 
factors that were found to be significantly different between groups. In addition, after 
controlling for non-specific effects, significant deficits in DNIC remained for the IBS group 
compared to controls on measures of changes in APR and MPR, but not THR. 
 There were significantly higher levels of psychological distress on measures on state 
anxiety, depression, anger-out expression style, and catastrophizing pain coping style in the 
IBS group compared to controls. After controlling for psychological measures of IBS 
subjects having other chronic pain conditions, group differences were unchanged for the state 
anxiety measure, depression, the catastrophizing coping strategy, and demonstrated a strong 
trend for the anger-out measure. 
 There were no group differences on any of the measures of temporal summation 
between groups. There also were no group differences on any of the measures of the DNIC 
effect on Temporal Summation. There were also no group differences on any of the general 







The results of the present investigation demonstrate deficits in endogenous analgesic 
mechanisms for patients with IBS. The recruitment of DNIC was significantly impaired in 
IBS subjects compared to controls, but unexpectedly, no group differences were observed in 
temporal summation or the DNIC effect on temporal summation. After controlling for IBS 
subjects diagnosed with a second chronic pain condition, the DNIC effects remained 
significantly compromised in IBS subjects. Significant group differences were also seen in 
anxiety, depression, anger expression style, and pain coping style. After controlling for 
psychological factors, which are known to be associated with both pain ratings, and DNIC, 
IBS subjects continued to show deficient DNIC. In addition, after controlling for non-specific 
effects on DNIC, IBS subjects continued to demonstrate dysregulation in DNIC compared to 
controls. This is an important innovation in attempting to isolate the physiological 
mechanisms of DNIC during psychophysical investigations. 
Distraction 
One of the strengths of this investigation was the design control of the effects of distraction 
on DNIC outcome measures. This was accomplished by including a protocol utilizing a non-
painful conditioning stimulus in addition to a standard, painful conditioning stimulus 
protocol. This allowed for analysis of a controlled measure of the degree to which thermal 
pain ratings change, specifically as a result of heterotopic cold pain and excludes the non-
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specific effects of the neutral water temperature session, which mirrored the noxious 
condition in every way except water temperature.  
 Painful conditioning stimuli are certainly a potential source of distraction (Plaghki et 
al., 1994), which has been shown to play a role in some studies on DNIC (Lautenbacher et 
al., 2002), but not in others (Pertovaara et al., 1982; Talbot et al., 1987). Riley and Levine 
(1988) showed that distraction from pain is most likely to occur when the conditioning 
stimulus and testing stimulus are very similar in perceptual quality (eg. heat vs. heat). The 
notion that perceptual similarity influences the degree of distraction may also explain why 
some types of clinical pain effect experimental pain procedures in some studies (Willer et al., 
1990), but not others (Ekblom & Hansson, 1987; Sigurdsson & Maixner, 1994). It has been 
suggested that distraction may have contributed to the effects of earlier DNIC studies (Staud 
et al., 2003; Lautenbacher & Rollman, 1997). To address this important issue, Staud and 
colleagues (2003) designed an investigation to address the role of distraction in DNIC. 
Subjects were instructed to attend to either the painful TS or the painful CS (in 
counterbalance order) of the same quality (heat vs. heat) and then rate the pain from the other 
stimulus immediately after the end of the presentation of stimuli. They found that only 
female FMS subjects demonstrated a distraction effect beyond the DNIC effect found in 
these subjects. Although distraction does not completely explain DNIC (Reinert et al., 2000; 
Willer et al., 1989; Willer et al., 1999), Longe et al. (2001) demonstrated that attention has a 
major influence on modulation of pain. In this study, instructions to attend to non-painful 
vibratory CS significantly reduced pain ratings compared to attending to painful concurrent 
stimuli (Longe et al., 2001). Tracey (2004) suggested that brain regions that are involved in 
hypervigilance may connect to brainstem structures responsible for DNIC leading to 
dysregulation in DNIC. Further, Reinert et al. (2000) speculated that hypervigilance to TS 
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during DNIC protocols may disrupt DNIC, especially if the test stimulus is meaningful, such 
as rectal distension for IBS patients (Reinert et al., 2000), as seen in the Wilder-Smith IBS 
investigation of DNIC. The present investigation assessed the DNIC effect using somatic 
pain for both the test and conditioning stimuli, in part to avoid interference from peripheral 
sensitization that may be present in IBS patients. It is believed that by using somatic pain TS 
and CS, dysregulation in central pain mechanisms were isolated when compromised DNIC 
was identified in IBS patients.  
 Although there were no group differences during the non-painful conditioning 
protocol in the present investigation, there were substantial decreases in pain ratings shown 
by both IBS and control groups during 320 C conditioning stimuli. This reflects non-specific 
effects that have rarely been accounted for in previous investigations of DNIC. While several 
investigators have used similar counterbalanced conditioned stimuli protocols to compare 
DNIC effects in noxious and non-conditioning stimulus protocols (Sigurdsson & Maixner, 
1994), only one other investigation has attempted to account for the role of non-specific 
effects in DNIC outcome measures (Edwards et al., 2003b). Edwards and colleagues (2003b) 
first identified the importance of isolating the DNIC effect from non-specific effects that are 
invariable part of all DNIC studies that utilize subjective reporting of pain ratings. Perhaps 
the most important findings in the present investigation are the robust group differences in 
DNIC that remained after controlling for distraction and psychological effects on pain ratings 
during counter-irritation protocols. Interestingly, this was true for protocols using phasic 
noxious test stimuli, but not when slow ramp heat was used as the test stimulus for changes 
in pain threshold. This may suggest that non-specific effects may have contributed to DNIC 
effects on pain threshold using slow-ramp TS that were reported in the majority of previous 
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studies on DNIC. It is recommended that future investigations examine the role of distraction 
and the degree to which it may contribute to abnormalities found in DNIC. 
Lack of Association between Endogenous Analgesic Mechanisms and Simple Pain 
Measures 
All of the simple pain measures were significantly correlated with each other and all of the 
DNIC measures were significantly correlated with each other, but none of the general pain 
measures were associated with any of the DNIC measures. Pielsticker et al. (2005) reported 
that chronic headache patients with deficient DNIC did not have lower pain thresholds, and 
concluded that the stimuli during THR testing was insufficient to recruit DNIC. Other 
investigators have failed to recruit a DNIC effect on pain threshold during counter-irritation 
as well (De Tomasso, 2003; Flor 2004). The present investigation found that non-painful 
conditioning stimuli led to reduced pain ratings. Lautenbacher and colleagues also found that 
non-noxious stimuli generated DNIC (Lautenbacher & Rollman, 1997; Lautenbacher et al., 
2002). They suggest that a sufficient number of nociceptors may be fired to recruit DNIC 
even when conditioning stimulus was not describes as painful. Lautenbacher (Lautenbacher 
et al., 2002) theorized that because ascending pain signals travel different spinal tracts than 
the descending inhibitory signals, they are likely to have different activation thresholds. This 
may explain the lack of concurrence between experiencing pain and DNIC induction (De et 
al., 1990). Alternatively, these results may reflect distraction or other non-specific effects that 
were not accounted for as was done in the present investigation.  
 Edwards et  al. (2003b) also found that the magnitude of DNIC was not associated 
with any other pain measures (THR, TOL, supra-threshold thermal pain ratings, or magnitude 
of temporal summation measures) and concluded that endogenous pain systems are 
subserved by different mechanisms than are these less complex pain responses. The authors 
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suggested that DNIC may be a more clinically relevant laboratory pain process than THR or 
TOL or simple pain rating scores, because it directly measures central nervous system pain 
regulatory mechanisms. In an attempt to identify what factors were associated with DNIC, 
Edwards and colleagues performed a hierarchical regression to parse out variables that were 
associated with DNIC variability (Edwards et al., 2003b). They found that DNIC predicted 
17% of the bodily pain subscale scores on the Short-Form 36 quality of life scale, but found 
no association between DNIC measures and cardiovascular function or hypothalamus-
pituitary-adrenal activity. They further found that DNIC was not mediated by psychological 
mechanisms, including: self efficacy, perceived stress, negative mood, positive mood, or 
greater stress reactivity. Edwards suggested that this may indicate a specific pain modulatory 
system for DNIC that is independent from other inhibitory systems and that enhancing pain 
modulatory ability may yield successful treatment for chronic pain sufferers (Edwards et al., 
2003b). The results of the present study are in agreement with Edwards (2003b). While many 
studies have identified differences in psychological factors or autonomic dysregulation for 
IBS patients, the fact that these variables do not appear to be associated with abnormalities in 
endogenous analgesic mechanisms suggests that psychological and autonomic factors may 
simply be co-morbid conditions, or possibly a consequence of long-term suffering form 
chronic pain condition such as IBS and not a causative factor as has often been suggested. 
Temporal Summation 
There were no significant group differences in temporal summation in the present 
investigation. Similarly, there were no group differences in the DNIC effect on temporal 
summation. Given the consistent reports of exaggerated temporal summation in other chronic 
pain conditions, this was an unexpected finding. This may have been due to a general lack of 
wind-up being elicited in the protocols that were employed. Small slope and Delta values 
  60
indicated that very little, if any temporal summation occurred. Hence it is unlikely that a 
DNIC effect on temporal summation, or perhaps even group differences in temporal 
summation could be detected due to floor effects. Reasons for recruiting minimal temporal 
summation may be due to conservative parameters selected for noxious stimuli or may be 
due to limitations of the instrumentation settings. Two phasic pain protocols were used. One 
set peak thermode temperatures at 500 C, whereas other investigations demonstrating 
enhanced temporal summation have used 530 C. The second protocol used individualized 
thermode temperatures based on slow-ramp heat pain tolerance temperatures. Slopes for the 
individualized thermode temperature were less than 1.0 (controls had a negative slope) and 
less than 2.0 for the more noxious thermode temperature protocol (500 C). Again, floor 
effects may limit the conclusions that can be drawn from the investigations regarding 
temporal summation in IBS. Further research is needed to elucidate whether IBS patients 
suffer from exaggerated temporal summation. Making certain that the noxious stimulus is 
sufficiently painful will help too ensure that temporal summation is recruited. This is 
required to be able to detect group differences, if in fact they exist. In addition, new 
equipment is now available that can provide much faster thermal pulses such that wind-up 
can be more consistently recruited. 
Psychological Factors 
Controlling for catastrophizing in the present study did not alter the results showing IBS 
deficits in DNIC for Average Pain Ratings, but group differences only showed a trend for 
group differences in DNIC scores for Maximum Pain Ratings. In addition to catastrophizing, 
the DNIC effect for Maximum Pain Ratings was also negatively correlated with IBS 
symptom severity, but not with other psychological measures, or sympathetic nervous system 
activity scores. Pain coping styles, especially catastrophizing, shape pain response to a 
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significant degree (Edwards et al., 2006b; Buenaver et al., 2007). Edwards found 
catastrophizing to be associated with elevated levels of temporal summation (Edwards et al., 
2006b) and suicidal ideation (Edwards et al., 2006a). Based on these results and those of the 
present study, the use of maximum pain scores may not be as reliable as average pain scores. 
It appears as though the tendency to catastrophize, seen in IBS patients, may artificially drive 
up maximum pain scores more so than average pain scores.  
 Although anger-out was not significantly associated with DNIC measures, IBS 
patients scored significantly higher than HC. In addition, there was no difference in anger-in 
scores between groups. Bruehl (2006a) and others (Kerns et al., 1994; Materazzo et al., 2000) 
have reported that scores on the Anger-Out Index were associated with elevated pain 
sensitivity and greater chronic pain intensity. In addition, Bruehl  (2006b; 2006c) has shown 
that deficits in opioid analgesia in chronic pain patients, as well as in HC, were associated 
with anger-out expression, which suggests that these impairments are not the result of 
chronic pain conditions. Anger-in was not associated with opioid dysfunction (Bruehl et al., 
2006b; Bruehl et al., 2006c). The authors suggested that anger-out expression may create 
increases in interpersonal stress, and the release of more opioids, which depletes the system, 
or may even create tolerance to endogenous opioids. More recently, Bruehl (2006c) and 
others (Burns et al., 2004), have shown that an anger out style of anger expression is 
associated with pain sensitivity and that this association depends on endogenous opioidergic 
anti-nociceptive dysfunction, whether indexed by circulating endogenous opioids or by 
opioid blockade. They further suggest that use of opioids medications may compensate for 
deficits in endogenous opioidergic analgesic systems. The present study found a combination 
of elevations in anger-out expression as well as a deficiency in endogenous analgesic systems 
in IBS subjects. This is consistent with the findings of Bruehl and the suggestions that IBS 
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patients suffer form dysregulation in serotonergic systems. Because DNIC effects are known 
to be largely serotonergic (Chitour et al., 1982), abnormalities in serotonin reuptake 
transporter polymorphisms seen in IBS suggests that failing DNIC may partially explain the 
success of selective serotonin reuptake inhibitor (SSRI) seen in the pharmaceutical treatment 
for some IBS patients. Selective serotonin reuptake inhibitors are known to improve motility, 
which may aid in pain reduction for IBS patients with constipation. It is widely 
acknowledged that improvement in symptoms offered by SSRIs may relate to improvement 
in mood. It is also believed that SSRIs offer direct analgesic effects, though this has not been 
proven. Conversely, a recent study determined that the SSRI, paroxitine, did not produce 
analgesic effects in comparison to maprotiline, a norepinephrine reuptake inhibitor. This may 
suggest an indirect mechanism of action for serotonin through it’s effect of norepinephrine.  
 Although antidepressants are still prescribed for patients with IBS, newer the serotonergic 
agents, tegaseraod and cilansetron, which are gut specific appear to be replacing traditional 
SSRI in the treatment of IBS. These agents are prescribed for constipation and diarhea 
predominant IBS, respectively, with the mechanism for pain relief being associated with 
changes in motility. Future investigations should identify associations between successful 
pharmaceutical treatment and the likely mechanism of deficient DNIC 
Summary 
The present investigation of endogenous analgesic mechanisms in IBS is the first study to 
extensively control for alternative explanations for the findings of compromised DNIC. In 
addition to controlling for hormonal and psychological factors by exclusion criteria, 
sympathetic arousal during pain testing and psychological factors found on questionnaires 
were statistically controlled for in secondary analyses. Most importantly, the design control 
for non-specific effects allowed for isolating the analgesic mechanisms from distraction and 
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other non-specific effects. Group differences in phasic DNIC measures remained significant 
even after controlling for this array of non-specific effects that are known to influence DNIC 
scores. Thus, the group differences in DNIC can be attributed to dysregulation in endogenous 
analgesic mechanisms in patients with IBS with confidence.  
 Wilder-Smith et al. (2004) previously demonstrated deficits in DNIC in IBS subjects 
using a visceral test stimulus and somatic conditioning stimulus (Wilder-Smith et al., 2004). 
Unfortunately, it can not be determined if the reduction in median pain scores for HC was 
due to distraction or whether the lack of DNIC in IBS subjects was due to hypervigilance to 
the test stimulus of rectal distensions, as suggested by Reinert et al. (2000) and Tracey et al. 
(2004). We have extended the findings of the Wilder-Smith study and improves on the design 
by controlling for non-specific effects in several important ways: 1) non-specific effects were 
controlled for by counter-balancing two CS protocols. One utilized a noxious conditioning 
stimulus (120 C water submersion of the hand), while the other provided the identical stimuli 
(circulating water) in a non-noxious form (320 C), 2) the effects of IBS patients with 
additional chronic pain syndromes were excluded, without affecting the results of the study, 
even with the reduction in power (this was not addressed in the Wilder-Smith study), 3) any 
significant group differences in psychological measures were controlled for by adding those 
measures as covariates in the relevant analyses.  
 There has been an increased interest in attempting to identify physiological 
mechanisms that contribute to functional chronic pain conditions, like FMS, TMD, and IBS. 
Recent studies have identified a post-infectious subgroup of IBS patients found to suffer 
form abnormalities in immunological function following an infection in the gastrointestinal 
tract that is believed to contribute to the development of IBS. There have also been several 
studies that have recently identified polymorphisms in serotonin reuptake transporter genes 
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in IBS patients. Multiple studies, including, the present one, have also demonstrated 
significant elevations in psychological distress, often associated with pain sensitivity. This is 
the second investigation, following Wilder Smith et al. (Wilder-Smith et al., 2004) to identify 
dysregulation in endogenous analgesic mechanisms for IBS. However, this is the first study 
to adequately control for non-specific effects that are known to contribute to DNIC effects. 
Limitations of this Study 
Failure to identify abnormalities in temporal summation may have been due to the use of test  
stimuli that was not sufficiently painful, limitations of the equipment to provide sufficiently  
rapid oscillations in phasic pain stimuli, or both. Replication of this investigation using newly 
available instrument capable of much faster delivery of stimuli along with increasing the  
temperature to 530 C, as has been done elsewhere, may yield different results. 
 Although removing non-specific effects from the DNIC effect is an important finding, 
this was accomplished through statistical means. Isolating the mechanisms responsible for  
DNIC through direct observation of those mechanisms, such alterations in fMRI activity 
(Wilder-Smith et al., 2004), or the RII reflex (Sandrini et al., 2006) will improve upon our  
understanding of physiological mechanisms that contribute to functional pain disorders.  
Future Research 
Although the conclusions that can be drawn form the Wilder-Smith investigation of DNIC in 
IBS patients are limited, their observations of abnormalities in fMRI activity in pain 
processing areas of the brain during the DNIC procedure provides insight into the  
mechanisms that may be involved in DNIC for IBS patients. Just published results report that 
deficient DNIC effects were also identified for abnormalities in the RIII nociceptive reflex in 
patients with migraines (Sandrini et al., 2006). These strategies provide an important 
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advancement in the study of DNIC in chronic pain disorders, allowing for the isolation of the 
DNIC mechanism from non-specific effects. 
 Whether deficits in DNIC are a cause or consequence of chronic pain is not known, 
but the relationship between DNIC and pain scores in healthy subjects suggests that 
compromised DNIC is not likely to entirely be a consequence of having chronic pain 
(Edwards et al., 2003b). Pielsticker et al. (2005) reported that while deficient DNIC was only 
weakly correlated with headache intensity, it may predispose individuals to developing 
chromic headache, but not be  relevant for sustaining headache later on. On the other hand, 
Kosek et al. (2000b) showed that osteoarthritis patients lacked DNIC (compared to HCs) 
when in pain, but recovered DNIC after surgery when they were pain free. This supports the 
idea that DNIC may be a consequence of chronic pain rather than a cause. Further long-term 
studies into whether disinhibition of pain in healthy individuals leads to IBS are needed. 
Conclusion  
In conclusion, the present study showed that IBS patients demonstrated compromised 
inhibitory regulation of phasic somatic pain stimuli. This disinhibition was independent of 
autonomic or psychological mechanisms, including distraction. It is hoped that these findings 
will contribute to the understanding of the role that central pain dysregulation plays in IBS 





Demographic/medical history questionnaire. This questionnaire was developed for the 
purposes of screening patients referred for evaluation of irritable bowel syndrome, as well as 
fecal incontinence, pelvic floor dyssynergia, functional dyspepsia, and other functional and 
motility disorders of the gastrointestinal tract. It is used to provide a systematic medical 
history with respect to these complaints, and to characterize the bowel habits of the patients. 
It includes questions on prior health care utilization. Demographic data on gender, age, 
educational level, and ethnicity are also included. This questionnaire has been given to 
approximately 5000 gastroenterology medical clinic patients in three states (North Carolina, 
Washington state, and California). Tests of the validity of the questionnaire have been limited 
to the symptoms used to diagnose IBS by the Rome criteria: At each of two clinics, 25 
patients who met Rome criteria for IBS based on the questionnaire and 25 patients who did 
not were selected at random and submitted to experienced clinicians who reviewed the charts 
blindly without reference to the questionnaire. Agreement with the questionnaire was similar 
for the two clinicians: sensitivity, 73% and 86%; specificity 56% and 64%(Levy et al., 
2000a) . 
The Irritable Bowel Syndrome Severity scale has been shown to be valid and reliable. In the 
original validation study of the scale (Francis et al., 1997), it was found to discriminate IBS 
patients from controls, and to discriminate between patients categorized as mild, moderate, 
and severe by independent clinical assessment. Test-retest reliability was judged to be 
excellent (Francis et al., 1997). Whitehead and colleagues adapted the IBSS slightly 
(Americanized the English) and administered it to 1603 patients with functional bowel 
disorders including 815 who met Rome II criteria for IBS. The IBSS correlated well 
(Spearman’s rho=.66; p<.0001) with the Functional Bowel Disease Severity Index(Drossman 
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et al., 1995) and also correlated with the frequency of medical clinic visits for IBS in the past 
6 months (r=.21; p<001). Internal consistency was adequate, with a standardized item 
Chronbach’s alpha of .73. In their systematic review of outcome measures in IBS clinical 
trials, Bijkerk et al (2003) (Bijkerk et al., 2003) ranked the instrument as one of the two best 
outcome measures for IBS trials based on psychometric properties.  
Physical Symptoms Questionnaire (Palsson et al., 2002) assessed levels of somatization. This 
questionnaire was developed to identify the somatic symptoms that are reported with 
increased frequency by patients with IBS. The RPSQ consists of 26 physical symptoms. 
Patients are asked to rate the frequency of occurrence of these symptoms in the last 30 days 
on a 5-point ordinal scale. A validation study was performed on 60 patients meeting Rome II 
criteria for IBS. The Cornell Medical Index (Abramson et al., 1965) was used to assess 
convergent validity. The internal consistency (Chronbach’s alpha) for this questionnaire is 
.86, the split-half reliability is .84, and the test-retest reliability is .84 (p<.0001). The 
correlation with the Cornell Medical Index validity was r=.85. The RPSQ also correlates 
strongly with number of physician visits in the past year (r=.62). 
The State-Trait Anxiety Inventory (Spielberger et al., 1983) has two versions both consisting 
of 20 adjectives/self-descriptions.  Subjects rate the extent to which they feel that they match 
the statements. One version requires subjects to rate how they presently feel (state anxiety), 
and the other version asks subjects to report how they generally feel (trait anxiety). Both 
versions were used for both studies.  For the trait anxiety scale, Spielberger et al. report that 
test-retest reliabilities range from .76 to .84 for 1 hour retesting, from .71 to .86 over 30 days, 
and from .65 to .77 over 60 days. Median Chronbach’s alpha for trait anxiety was .90.  Due 
to the anticipated transitory nature of state anxiety, test-retest reliabilities for the state anxiety 
measure are only in the low to moderate range.  Median Chronbach’s alpha for state anxiety 
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is .93.  Factor analysis of the items confirms a two-factor (state and trait anxiety) solution for 
the instrument. Spielberger et al. report that the scales correlate highly with other measures of 
anxiety, that the state anxiety measure is sensitive to induced anxiety states such as those 
produced experimentally, and that trait anxiety shows good utility in identifying clinical 
populations with anxiety or anxiety related problems. Okun, Stein, Bauman, and Silver 
(1996) found that the trait measure of the instrument performed fairly well in measuring five 
of eight factors used to diagnosis generalized anxiety disorder in the DSM-IV.  
Speilberger Anger Expression Index (Spielberger et al., 1995):  This assessment was used to 
determine state and trait levels of anger, as this construct has been shown to be related to 
cardiovascular activity.  The Anger Expression Index has well documented reliability and 
validity(Spielberger et al., 1995). 
Perceived Stress Scale (Cohen et al., 1983) This assessment consists of 14 items which are 
evaluated on a 5-point Likert scale.  The items on the PSS tap into the degree to which 
individuals feel that events in their lives are unpredictable and uncontrollable.  Validity and 
test-retest reliabilities have been demonstrated for this scale will measure recent exposure 
and responses to stress(Cohen et al., 1983).  
Coping Strategies Questionnaire  (Rosenstiel & Keefe, 1983) was used to measure pain 
coping/pain responsivity. Cognitive and behavioral pain coping strategies were assessed by 
means of a questionnaire in a sample of 61 chronic low back pain patients. Data analysis 
indicated that the questionnaire was internally reliable. While patients reported using a 
variety of coping strategies, certain strategies were used frequently whereas others were 
rarely used. Three factors: (a) Cognitive Coping and Suppression, (b) Helplessness, and (c) 
Diverting Attention or Praying, accounted for a large proportion of variance in questionnaire 
responses. These 3 factors were found to be predictive of measures of behavioral and 
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emotional adjustment to chronic pain above and beyond what may be predicted on the basis 
of patient history variables (length of continuous pain, disability status, and number of pain 
surgeries) and the tendency of patients to somaticize. Each of the 3 coping factors was related 
to specific measures of adjustment to chronic pain (Rosenstiel & Keefe, 1983) 
Catastrophizing subscale of the Coping Stratgies Questionnaire (Hirsh et al., 2006) will 
assess levels of catastrophizing as a coping style. Measurement and conceptual issues of pain 
catastrophizing have been raised in the literature. The issues of construct redundancy and 
measurement overlap have received particular attention, with suggestions that measures of 
pain catastrophizing are confounded with measures of negative mood, namely depression. 
The current study sought to investigate these issues in the coping strategies questionnaire-
catastrophizing subscale, a widely used measure of pain catastrophizing. Chronic pain 
patients (n=152) were recruited from the University of Florida pain clinics and completed a 
battery of psychological measures. Regression analyses indicated that measures of 
depression, anxiety, and anger accounted for 69% and 19% of the variance in measures of 
pain catastrophizing and pain, respectively. Trait anger and the cognitive and fearful 
dimensions of depression and anxiety were uniquely associated with pain catastrophizing. 
After controlling for measures of negative mood, pain catastrophizing contributed minimally 
to the prediction of pain. This study suggests that the catastrophizing is highly related to 
measures of negative mood and raises doubts about its measurement of the construct of pain 
catastrophizing. Results also provide support for theoretical accounts of the relationships 
between pain catastrophizing, negative mood, and pain. Clinical implications, future research 
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